AAVBC

American Academy of Value Based Care

Breast Cancer

Quick Coding Guide

2026

AAVBC Breast Cancer Quick Reference Guide

Table of Contents

1. CLINICAL SNAPSHOT..... 2
2. RECOGNITION & DIAGNOSIS..... 3
Medicare Screening & Diagnostic CPT Reference..... 4
Guideline Breast Cancer Screening Recommendation Comparison (2024–2026).....5
Right time: When to screen..... 6
AAVBC Stance on Screening.....6
Extent of Disease.....8
Conformational Diagnostic Tools..... 9
Post-diagnosis evaluation.....11
Disease Staging.....12
Survival Rates.....14
The Financial Impact of Breast Cancer Staging..... 15
Risk Factors..... 16
Red Flags - Urgent Action..... 17
Diagnostic Thresholds.....19
Clues to Dig Deeper..... 19
Common Oversights..... 20
Key Differentials.....21
Comorbidity Screening..... 21
Staging/Severity Matrix..... 22
3. MEAT DOCUMENTATION ESSENTIALS.....24
Clinical Documentation Elements.....24
4. TREATMENT & REFERRAL QUICK GUIDE.....25
Therapy Escalation Criteria..... 25
Non-Rx Treatment Documentation..... 33
Patient Education & Adherence.....35
Comorbidity Management.....35
Cost-Smart Options.....36
Quality Metrics Tie-In.....36
5. CODING REMINDERS & CASE EXAMPLES BOX..... 37
Specificity Requirements.....37
Brief Case Examples.....38
Appendix.....40
REFERENCES..... 48

1. CLINICAL SNAPSHOT

Definition: Breast cancer is a heterogeneous malignant neoplasm originating from the epithelial cells of the terminal duct lobular unit. It is characterized by dysregulated cellular mitosis, local tissue invasion, and the potential for hematogenous or lymphatic metastasis.[1]

ICD-10 Codes and HCC/RAF V28:[2]

ICD-10 Code	Description & Specificity Requirement	HCC Mapping	RAF Weight
C50.X	Malignant neoplasm of breast. Must specify Laterality (1=R, 2=L, 9=Unspecified) and Gender (1=F, 2=M)	HCC 23	0.186
C50.A	Malignant inflammatory neoplasm of breast. Use C50.A1 for Right or C50.A2 for Left	HCC 23	0.186
C78.0	Secondary malignant neoplasm of the lung. Represents metastatic spread to the lungs	HCC 17	4.209
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct	HCC 17	4.209
C79.31	Secondary malignant neoplasm of brain	HCC 17	4.209
C79.51	Secondary malignant neoplasm of bone	HCC 18	2.341
Z85.3	Personal history of malignant neoplasm of breast. Use for survivors not on active treatment	None	0.000
Z51.0	Encounter for antineoplastic radiation therapy	None	0.000
Z51.11	Encounter for antineoplastic chemotherapy	None	0.000
Z51.12	Encounter for antineoplastic immunotherapy	None	0.000

Abbreviations: HCC, Hierarchical Condition Category; ICD-10, International Classification of Diseases, 10th Revision; L, Left; R, Right; RAF, Risk Adjustment Factor; V28, Version 28 CMS-HCC Model

Prevalence: Approximately **4 million Americans** are currently living with breast cancer. For the 2025–2026 period, it is estimated that: 316,950 women will be diagnosed with invasive breast cancer[3]; 59,080 women will be diagnosed with *in situ* (non-invasive) lesions, such as Ductal Carcinoma in Situ; 2,800 men will be diagnosed with invasive breast cancer.

Breast cancer accounts for more than ~14% of oncology spending ($29.8B, 2020); and the cost per-member per year (PMPY) fluctuates based on the patient's journey:

Phase of Care	Estimated Annual Medical Cost (PMPY)	Estimated Annual Pharmacy Cost (PMPY)
Initial Care (Months 1–12)	$35,000 – $43,400	$1,100 – $2,500
Continuing Care (Interim Years)	$3,500 – $9,500	$830 – $1,500

Phase of Care	Estimated Annual Medical Cost (PMPY)	Estimated Annual Pharmacy Cost (PMPY)
End-of-Life Care (Final 12 Months)	$76,100 – $137,000	$2,700 – $5,000
Abbreviations: PMPY (per member per year)		

2. RECOGNITION & DIAGNOSIS



Breast cancer screening recommendations differ slightly across professional organizations. The variation centers on:

- **Starting age**
- **Screening interval (annual vs biennial)**
- **Upper age limits**
- **High-risk management**

Primary care clinicians should individualize screening based on patient risk, overall health status, and shared decision-making.

Medicare Screening & Diagnostic CPT Reference

Clinical Scenario	Service	CPT Code	Medicare Coverage (Part B)	Notes/Concise Use Case
Average-Risk Screening (Age ≥40)	Screening mammography (bilateral)	77067	Covered annually	Preventive screening; use Z12.31
	Digital Breast Tomosynthesis (add-on)	77063	Covered when performed with 77067	3D imaging; preferred for dense breasts

Clinical Scenario	Service	CPT Code	Medicare Coverage (Part B)	Notes/Concise Use Case
Abnormal Screening or Breast Symptoms	Diagnostic mammography (unilateral)	77065	Covered when medically indicated	For abnormal screening result or focal symptoms
	Diagnostic mammography (bilateral)	77066	Covered when medically indicated	Bilateral diagnostic evaluation
	Targeted breast ultrasound	76642	Covered when medically indicated	Evaluate palpable mass or imaging abnormality
High-Risk Patient (BRCA, ≥20–25% lifetime risk, prior chest radiation)	Breast MRI (bilateral)	77049	Covered when high-risk criteria documented	Adjunct to mammography; not standalone screening
Image-Guided Biopsy	Ultrasound-guided biopsy	19083	Covered when medically necessary	Most common biopsy method
	Additional lesion biopsy (add-on)	+19084	Covered	For separate lesion sampling
	Stereotactic biopsy	19081	Covered	Mammography-guided biopsy
Established Breast Cancer	Partial mastectomy (lumpectomy)	19301	Covered	Surgical treatment of active malignancy (C50.x)
	Simple mastectomy	19303	Covered	
	Sentinel lymph node biopsy	38525	Covered	Staging procedure
Systemic Therapy Administration	IV chemotherapy (initial hour)	96413	Covered	Active cancer required
	Additional infusion hour	96415	Covered	
Post-Treatment Surveillance	Diagnostic mammography	77065–77066	Covered when surveillance indicated	Ongoing evaluation if active monitoring
	Screening mammography	77067	Covered annually	Use after transition to history status (Z85.3)

Guideline Breast Cancer Screening Recommendation Comparison (2024–2026)

Organization	Population/Risk Level	Recommendation	Frequency & Age Details
American Cancer Society (ACS)	Average Risk	Mammogram	Ages 40–44: Option to start annually Ages 45–54: Every year Ages 55+: Every 2 years or continue annually if in good health (10-year life expectancy)

Organization	Population/Risk Level	Recommendation	Frequency & Age Details
	High Risk (20-25% + Lifetime Risk)	Mammogram + Breast MRI	Age 30+: Annually. Includes: BRCA mutations, 1st-degree relative with BRCA, chest radiation <30y/o, or specific syndromes (Li-Fraumeni, Cowden)
	Low/Moderate Risk (<15% Lifetime)	MRI not recommended	ACS recommends against MRI for women with <15% lifetime risk
U.S. Preventive Services Task Force (USPSTF)	Average Risk	Mammogram	Ages 40–74: Biennial (every other year) screening
	Ages 75+	Evidence Insufficient	Current evidence is insufficient to assess the balance of benefits vs. harms
	Dense Breasts	Evidence Insufficient	Evidence is insufficient to assess supplemental screening (ultrasound or MRI) if mammogram is negative
American College of Radiology (ACR)	Average Risk	Mammogram	Age 40+: Strongly advocates for annual screening
ACOG (OB-GYNs)	Average Risk	Mammogram	Ages 40–75: Every 1 to 2 years based on shared decision-making regarding benefits/harms Ages 55+: Biennial is a reasonable option to minimize harm
	Ages 75+	Shared Decision-Making	Decision based on health status and life expectancy; do not discontinue based on age alone
	Physical Exams	Clinical Breast Exam (CBE)	Ages 25–39: Every 1–3 years Ages 40+: Annually
	Self-Awareness	Breast Self-Awareness	Encouraged to help detect palpable cancer; however, routine breast self-exams (BSE) are not recommended

* Lifetime risk scores (i.e., 20%) are calculated using risk assessment tools based on personal and family history. Risk score is often calculated using the Tyrer-Cuzick or Gail model

Practical Takeaways

- **All major organizations now support starting screening at age 40**
- The primary difference is **annual vs biennial frequency**
- Screening is most beneficial when life expectancy exceeds 10 years
- For patients ≥75, screening decisions should reflect:
  - Overall health
  - Functional status
  - Life expectancy
  - Patient preference



Right time: When to screen

Every patient is different; applying a value-based approach to breast cancer screening requires tailoring efforts to patient needs and circumstances, such as their risk-level. Higher risk patients (>20% lifetime risk) should receive more proactive breast cancer screening. The following are indicators of a higher-risk patient:

- **Genetic mutations**: Carriers of BRCA1, BRCA2, or other gene mutations
- **Family history**: First-degree relatives (mother, sister, daughter) with breast or ovarian cancer, especially young or in both breasts, or male relatives with breast cancer
- **Personal history**: Previous breast cancer, lobular carcinoma in situ (LCIS), atypical hyperplasia, or radiation to the chest before age 30
- **Breast density**: Dense breast tissue
- **Hormonal factors**: Starting periods before 12, menopause after 55, or late first pregnancy (after 30)
- **Lifestyle**: Alcohol use, inactivity, obesity (especially post-menopause)
- Received **radiation therapy** to the chest between the ages of 10 and 30
- Have (or have a first-degree relative with) **Li-Fraumeni**, **Cowden**, or **Bannayan-Riley-Ruvalcaba syndromes**

AAVBC Stance on Screening

AAVBC supports a value-based breast cancer screening strategy rooted in prevention, early detection, and continuity of care.

AAVBC endorses ***annual*** **mammography beginning at age 40** for average-risk women, risk-stratified MRI for individuals at elevated risk, appropriate use of clinical breast examination, and patient-centered education that promotes breast self-awareness.

When screening is consistent and timely, breast cancer is more often detected at earlier stages which improves survival, reduces treatment burden, and supports long-term health.

Value-based care in breast cancer screening is not about reducing services. It is about ensuring the right screening occurs at the right time for the right patient, with closed-loop follow-up and shared decision-making.

BI-RADS–Key Imaging Screening & Decision Tool:

Breast Imaging Reporting and Data Systems Scoring (BI-RADS)[4]

The BI-RADS (Breast Imaging Reporting and Data System) categories provide standardized recommendations for the next steps in patient management, which often involve specific additional imaging or procedures. The BI-RADS is used by radiologists and health providers to **standardize reporting for breast imaging exams like mammograms, ultrasounds, and MRIs.**

It classifies findings from 0 to 6 to assess cancer risk and guide follow-up care, and also categorizes breast density (A-D) for mammograms. It helps doctors communicate results clearly, ensures consistent quality, and informs patients about their breast cancer risk and next steps, with categories indicating normal, benign, or suspicious findings.

BI-RADS Assessment Categories (0–6)

Category	Assessment	Estimated Risk	PCP Action
0	Incomplete	—	Ensure additional imaging is completed promptly
1	Negative	~0%	Continue routine screening
2	Benign	~0%	Continue routine screening
3	Probably benign	<2%	Arrange short-interval follow-up (usually 6 months)
4	Suspicious	Variable (2–95%)	Refer for biopsy
5	Highly suggestive of malignancy	≥95%	Urgent biopsy referral
6	Known biopsy-proven malignancy	Confirmed	Coordinate treatment/oncology

AAVBC Tip: Most breakdowns in care occur at:

- BI-RADS 0 (incomplete — no follow-up arranged beyond annual mammography)
- BI-RADS 3 (missed 6-month follow-up)

Closed-loop tracking is critical.

BI-RADS breast density categories (A-D) describe tissue composition, with A being fatty (easy to see cancers) and D being extremely dense (hard to see cancers), prompting imaging suggestions like supplemental ultrasound, MRI, or tomosynthesis for categories C and D to improve cancer detection, as

dense tissue can hide tumors and is a risk factor for breast cancer, although specific recommendations vary by region.

BI-RADS Breast Density Categories (A–D) & Imaging Suggestions

Density Category	Description	Mammographic Sensitivity & Detection	Supplemental Imaging Considerations
Category A	Almost Entirely Fatty	Composed mostly of fat with minimal fibroglandular tissue; abnormalities are highly conspicuous	Standard screening mammography is typically sufficient
Category B	Scattered Fibroglandular Densities	Predominantly fatty with scattered areas of density; most abnormalities remain visible	Standard screening mammography is typically sufficient
Category C	Heterogeneously Dense	Mixed dense and fatty tissue; the density may obscure small masses, increasing the difficulty of detection	Supplemental Screening: Ultrasound or DBT is often recommended to identify cancers obscured by tissue
Category D	Extremely Dense	Almost entirely dense tissue; significantly reduces mammographic sensitivity, making tumors very difficult to visualize	Mandatory Consideration: Ultrasound or MRI are highly recommended; DBT is standard to improve detection rates

Abbreviations: DBT, Digital Breast Tomosynthesis (DBT)

How is BI-RADS used in practice?

Example: A patient may have a BI-RADS score of 3, but their density category may be D. In this case, while their score would indicate a 6 month follow-up, their tissue density suggests they should have additional testing before 6 months. In this case, a patient would be advised to have an MRI, Digital Breast Tomosynthesis (DBT), or 3D mammography.

Extent of Disease

Imaging does not just provide a risk score for the patient or inform the provider or next steps in regards to follow-up care, but helps assess the extent of disease. Assessing the extent of local disease is a multidimensional process used to determine surgical eligibility (e.g., breast conservation vs. mastectomy) and plan adjuvant therapy. Accurate imaging identifies whether the cancer is localized, multifocal, or multicentric, which directly impacts surgical margins and recurrence risk.

Determining Extent of Local Disease

Term	Definition	Clinical Significance
Multifocal	Multiple tumors within the same quadrant	Often represents disease spread along a single ductal system

Term	Definition	Clinical Significance
Multicentric	Multiple tumors in different quadrants	Suggests involvement of multiple ductal systems; often precludes breast conservation
EIC	Extensive Intraductal Component: DCIS accounts for >25% of the tumor area	Predictor for widespread residual DCIS after initial excision; higher risk of positive margins
Intramammary Nodes	Lymph nodes found within the breast tissue itself	Metastasis here confers a worse prognosis, even if axillary nodes are negative

Abbreviations: BCS, Breast Conserving Surgery; DCIS, Ductal Carcinoma In Situ; EIC, Extensive Intraductal Component; MC, Multicentric; MF, Multifocal; MMBC, Multifocal and Multicentric Breast Cancer (used when grouping both entities)

Conformational Diagnostic Tools[5]

Diagnosis of **breast cancer is definitively established through a biopsy**, which must confirm the presence of invasive (malignant) cells in breast tissue. Once confirmed, the pathology report identifies the specific histologic type, which determines the cancer's behavior and treatment path.



Core Biopsy – Key Histological Findings

Histologic Type	Prevalence	Surgical Approach	Primary CPT Codes	Prognostic Outlook
Infiltrating Ductal (IDC/NST)	70–80%	Breast-Conserving Surgery (BCS) or Mastectomy	19301 (Partial Mastectomy/Lumpectomy)19307 (Modified Radical Mastectomy)	Variable: Directly correlates with molecular subtype (ER/PR/HER2)
Infiltrating Lobular (ILC)	8%	Higher rate of Mastectomy due to multifocality/diffuse	19303 (Simple/Total Mastectomy)19307 (Modified Radical)	Guarded Late: High risk for late recurrence (10+ years) and GI/peritoneal spread

Histologic Type	Prevalence	Surgical Approach	Primary CPT Codes	Prognostic Outlook
		growth		
Mixed Ductal/Lobular	7%	Often requires larger margins or Mastectomy to clear lobular "spider-web" cells	19301 (BCS) or 19303 (Total Mastectomy)	Hybrid: Behaves similarly to IDC but with the "occult" risk of ILC
Tubular/ Mucinous	<2%	Almost always candidates for BCS (Lumpectomy)	19301 (Partial Mastectomy)	Excellent: 10-year survival rates often >90%. Rarely involves nodes
Metaplastic	<1%	Aggressive surgical resection; often Mastectomy	19307 (Modified Radical Mastectomy)	Aggressive: Higher resistance to chemo; poorer prognosis than IDC

Abbreviations: IDC, Infiltrating Ductal Carcinoma; ILC, Infiltrating Lobular Carcinoma; NST, No Special Type; HR, Hormone Receptor; ER, Estrogen Receptor; PR, Progesterone Receptor; HER2, Human Epidermal Growth Factor Receptor 2; BCS, Breast-Conserving Surgery; CPT, Current Procedural Terminology; SLNB, Sentinel Lymph Node Biopsy; ALND, Axillary Lymph Node Dissection; AJCC, American Joint Committee on Cancer; TNM, Tumor, Node, Metastasis; pCR, Pathologic Complete Response; KCN, Key Clinical Note

Common Histological Diagnostic Terms

- **Invasive/Infiltrating:** Indicates that cancer cells have broken through the basement membrane of the ducts or lobules and invaded the surrounding **mammary stroma** (connective tissue)
- **Terminal Duct Lobular Unit (TDLU):** The specific functional unit of the breast where almost all epithelial breast carcinomas originate
- **Histologic Grade:** (e.g., Nottingham Grade) A score provided in the pathology report that describes how closely the cancer cells resemble normal cells (Differentiation)

Key Differentials

Breast cancer is a heterogeneous disease, and its differential diagnosis involves distinguishing primary invasive epithelial carcinomas from a variety of precancerous, non-epithelial, and rare malignant lesions. Mimics represent key differential diagnosis and warrant expert pathologic review of biopsies.

Category	Differential Diagnosis	Key Clinical/Pathologic Characteristics	Clinical Notes
Precancerous	Ductal Carcinoma in Situ (DCIS)	Malignant epithelial cells confined to ducts or lobules; **no invasion of the basement membrane**	Considered a precursor lesion. Pathology reports should specify **nuclear grade** and **comedonecrosis**, which indicates higher progression risk
Transitioning Lesion	Microinvasive Breast Cancer	Primarily DCIS with **focal invasion ≤1 mm**	Represents the **earliest measurable invasive stage**; frequently discovered incidentally in high-grade DCIS

Category	Differential Diagnosis	Key Clinical/Pathologic Characteristics	Clinical Notes
Skin Variant	Paget Disease of the Breast	**Scaly or ulcerated nipple/areola lesion** caused by malignant cells infiltrating epidermis	Often mistaken for eczema or dermatitis. Approximately **80% of cases have underlying IDC or DCIS**; frequently associated with **HER2-positive tumors**
Connective Tissue Malignancy	Breast Sarcoma	Malignancy arising from **stromal connective tissue** rather than epithelial breast tissue	Rare. May occur **de novo** or following **prior radiation exposure** or chronic lymphedema (Stewart-Treves syndrome)
Fibroepithelial Tumor	Phyllodes Tumor	Biphasic tumor with epithelial and stromal components; characterized by **stromal overgrowth**	Classified as **benign, borderline, or malignant**. Rapid growth may mimic invasive carcinoma clinically
Hematologic Malignancy	Breast Lymphoma	Most commonly **Non-Hodgkin B-cell lymphoma** presenting as breast mass or fluid collection	May appear as a **painless breast mass or seroma**. **Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)** is associated with textured implants

Post-diagnosis evaluation[6,7]



Receptor testing is an essential component of the initial breast cancer diagnosis. It identifies the biological drivers of the tumor, which dictates the AJCC Pathologic Prognostic Staging and determines the specific systemic therapy required.

Receptor Testing & Clinical Significance

Marker	Positivity Threshold	Clinical Significance
ER/PR	≥1% of cells staining positive	Predictive: Indicates the tumor will likely respond to endocrine (hormone) therapy
HER2	IHC 3+ (intense membrane staining) or FISH ratio ≥2.0	Targeted Therapy: Predicts benefit from HER2-directed therapies (e.g., Trastuzumab). Found in 15%–20% of cases

Abbreviations: ADC, Antibody-Drug Conjugate; AI, Aromatase Inhibitor; ASCO, American Society of Clinical Oncology; CAP, College of American Pathologists; ER, Estrogen Receptor; ET, Endocrine Therapy; FISH, Fluorescence In Situ Hybridization; HER2, Human Epidermal Growth Factor Receptor 2; IHC, Immunohistochemistry; PR, Progesterone Receptor; T-DXd, Trastuzumab Deruxtecan

Biological & Therapeutic Impact

- **Hormone Receptors (ER/PR):** These function as both prognostic and predictive factors. Positivity allows for the use of drugs that block estrogen (e.g., Tamoxifen or Aromatase Inhibitors)
- **HER2 (Human Epidermal Growth Factor Receptor 2):** Overexpression is confirmed via **IHC** (Immunohistochemistry) or **FISH** (Fluorescence In Situ Hybridization). Gene amplification (FISH ratio ≥2.0) indicates a more aggressive biological subtype that requires targeted blockade
- **Prognostic Staging:** Under the current AJCC system, a patient's stage is no longer determined by anatomy alone (size/nodes); receptor status can shift a patient's prognostic stage significantly

Disease Staging[4,8,9]



Blood Work Post-Diagnosis[10]

1. Routine Baseline & Staging Labs

These are ordered immediately after diagnosis to assess organ function before starting surgery, chemotherapy, or radiation.

Lab Test	Purpose in Breast Cancer	Clinical Rationale
CBC with Diff	Baseline Hematology	Checks for anemia, infection risk (WBC), and clotting ability (platelets). Repeated frequently during chemo
CMP	Organ Function	Assesses kidneys (Creatinine) and liver (AST/ALT/Bili) to ensure safe drug metabolism
Alkaline Phosphatase	Metastatic Screening	If elevated, it may signal spread to the bone or liver, triggering further imaging (Bone/CT scan)
Serum Calcium	Metabolic Monitoring	High levels (hypercalcemia) can be a sign of extensive bone metastases or parathyroid issues

Abbreviations: CBC, Complete Blood Count; Diff, Differential (White Blood Cell breakdown); WBC, White Blood Cell count; PLT, Platelets; CMP, Comprehensive Metabolic Panel; Cr, Creatinine; BUN, Blood Urea Nitrogen; AST/ALT, Aspartate/Alanine Aminotransferase; Bili, Bilirubin; ALP, Alkaline Phosphatase; Ca, Calcium; CTX, Chemotherapy; CT, Computed Tomography

2. Advanced Molecular & Genetic Blood Tests

In 2026, "Liquid Biopsies" and germline testing can be a part of guided targeted therapy. See more in the appendix.

- **Germline Genetic Testing (BRCA1/2):** Recommended for many newly diagnosed patients up to age 65 (and many over 65) to determine if the cancer is hereditary. This can influence the decision for bilateral mastectomy or the use of **PARP inhibitors**
- **ctDNA (Circulating Tumor DNA):** Often called a "Liquid Biopsy." In 2026, this is used to:
  - Identify specific mutations like **ESR1** or **PIK3CA** in metastatic disease to pick the right drug (e.g., Elacestrant)
  - **Key note:** Liquid biopsy to monitor circulating tumor DNA (ctDNA) is not considered standard, universal, or routine care for all breast cancer patients in the USA, but its adoption is rapidly increasing in clinical practice for advanced disease
- **ESR1 Mutation Testing:** Specifically used for patients with ER+/HER2 metastatic disease to determine eligibility for oral selective estrogen receptor degraders
- **MamaPrint:** MammaPrint is a genomic test used after an initial breast cancer diagnosis and surgical resection (biopsy or surgery) to determine a patient's specific risk of the cancer returning (recurrence) within 5 to 10 years. It is specifically used for early-stage breast cancer to decide if chemotherapy is necessary.
  - **Purpose and Timing:**
    - **Post-Surgical Planning:** MammaPrint is not used to diagnose cancer; rather, it is used after diagnosis, usually following surgery or a core needle biopsy, to inform post-operative treatment, particularly for deciding whether to add chemotherapy to hormonal therapy
    - **Risk Assessment:** It analyzes the activity of 70 genes in the tumor tissue to classify the patient as either Low Risk or High Risk of distant metastasis
    - **Predictive Value:** The main goal is to identify patients who are at low risk and can safely avoid the toxicity of chemotherapy, or those at high risk who would benefit from it
  - **MammaPrint is FDA-cleared for early-stage (Stage I or II) breast cancer patients, regardless of age, with the following criteria:**

- Invasive carcinoma (tumor size ≤5.0 cm)
- Lymph node-negative (no cancer in the lymph nodes)
- Estrogen receptor-positive (ER+) or -negative (ER-)
- HER2-negative or HER2-positive

Imaging Modalities Post-Diagnosis/Follow-up[9,11,12]

After Mastectomy (with Reconstruction or Without):

- No mammogram on the reconstructed or removed breast (unless nipple/tissue sparing)
- Annual mammograms on the unaffected breast

For High-Risk Patients/Genetic Mutations:

- May require supplemental screening like MRI or 3D mammography (tomosynthesis) in addition to annual mammograms, as advised by a specialist

For Advanced Stages (IIB, III):

- Initial staging may involve PET/CT scans (chest/abdomen) and bone scans, but routine use in asymptomatic follow-up is generally discouraged
- Neither the American Cancer Society (ACS) nor the American College of Obstetricians and Gynecologists (ACOG) recommend routine systemic imaging (CT/PET) for *early-stage* breast cancer (Stage I, II, or early Stage III) because the likelihood of metastasis is low, and the costs/risks outweigh benefits, but it *is* recommended for *locally advanced* (Stage IIB/IIIA+) disease and when conventional staging is unclear, to detect unexpected distant spread. National Comprehensive Cancer Network suggest PET/CT for Stage III/IV or suspicious equivocal findings in earlier stages, but not for early-stage, operable cancer where it can lead to over-treatment and unnecessary exposure
- **Younger Patients (<40):** Some evidence suggests PET/CT might be more beneficial in younger patients (under 40) due to higher rates of aggressive cancer subtypes (HER2+, TNBC) and potentially higher detection of distant spread, even in early stages

What's Not Routinely Recommended

- Routine CT, bone scans, or PET/CT for asymptomatic patients
- Routine MRI for surveillance, except in specific high-risk situations

Survival Rates

5-Year Relative Survival Rates for Breast Cancer[13,14]

SEER Stage	Definition	5-Year Relative Survival Rate
Localized (Stage 0/I)	Invasive cancer confined entirely to the breast with no sign of spread	>99%

Regional (Stage II/III)	Cancer has spread outside the breast to nearby structures or lymph nodes	86-87%
Distant (Stage IV/Metastatic)	Cancer has spread to distant parts of the body (e.g., lungs, liver, or bone)	30-32%
All Stages Combined	The average survival rate across all SEER stages	91%
Abbreviations: Surveillance, Epidemiology, and End Results Program		

Overall Survival Rates for Breast Cancer by Cancer Subtype[13,14]

Breast Cancer Subtype	Overall Survival	Localized Stage	Regional Stage	Distant Stage
HR+/HER2-	94.8%	100.0%	90.2%	34.0%
HR+/HER2+	91.0%	99.1%	89.8%	45.6%
HR-/HER2+	85.6%	97.2%	84.0%	39.5%
HR-/HER2- (Triple-Negative)	77.6%	91.8%	66.2%	12.8%
Abbreviations: ER, Estrogen Receptor; HER2, Human Epidermal Growth Factor Receptor 2; HR, Hormone Receptor (includes ER and/or PR); PR, Progesterone Receptor; TNBC, Triple-Negative Breast Cancer				

The Financial Impact of Breast Cancer Staging[15,16]

The economic burden of breast cancer is directly correlated with the stage at diagnosis. Early detection not only improves clinical outcomes but also significantly reduces the financial strain on the healthcare system and the patient.

First-Year Treatment Costs by Stage

Treatment for Stage III breast cancer typically costs 55–95% more than Stage I during the first year of care. This discrepancy arises because advanced stages necessitate more intensive, multi-modal therapies, including complex chemotherapy, surgery, and extended radiation.

Diagnosis Stage	Average First-Year Cost	24-Month Cumulative Cost
Stage I/II (Early)	~$82,121	~$97,066
Stage III (Regional)	~$129,387	~$159,442
Stage IV (Metastatic)	~$134,682+	Varies by therapy duration

Drivers of Cost Disparity:

- **Treatment Intensity:** Stage I often involves localized interventions, such as a lumpectomy followed by hormone therapy. In contrast, Stage III requires a combination of aggressive systemic and local treatments

- **Long-Term Burden:** The cost gap persists well beyond the initial diagnosis, with two-year costs for Stage III remaining substantially higher than for early-stage cases
- **Value of Screening:** Early detection is a high-value intervention. While the cost to detect one case of invasive cancer via screening is approximately **$44,000–$55,000**, this is significantly lower than the immediate $129,000+ required to treat regional or advanced-stage disease
- **The "Regional" Premium:** Delaying diagnosis from Stage I to Stage III results in a **95% average cost increase**. This "premium" is driven by the necessity of multi-modal care (aggressive chemotherapy, reconstructive surgeries, and extended radiation) that early-stage patients often bypass
- **Clinical vs. Economic Win-Win:** Early-stage treatment (Stage I) often allows for less invasive options like lumpectomies and hormone therapy, which not only reduce the financial burden but also significantly improve the patient's quality of life and long-term survival rates.

Key Takeaway: Shifting diagnosis from Stage III to Stage I can nearly halve the total cost of care while allowing for less invasive, more effective treatment options.

Subtle Early Signs[17]

The LMNOP Signs of Breast Cancer

- **L – Lump:** The most common sign is a new, palpable mass or thickening in the breast or underarm (axilla)
- **M – Mammography Changes:** Abnormalities detected on a screening mammogram, such as new masses or nonlinear branching microcalcifications, can indicate early disease even before a lump is felt
- **N – Nipple Changes:** This includes nipple retraction (pulling inward), persistent crusting, or raw, ulcerated lesions as seen in **Paget disease**
- **O – Orange Peel Skin (Peau d'orange):** A thickening of the skin that resembles the texture of an orange peel, often associated with **inflammatory breast cancer (T4d)**
- **P – Pain or Puckering:** While most early breast cancers are painless, new persistent pain in one spot or skin dimpling (puckering) caused by the tumor pulling on breast tissue should be evaluate
- **D – Discharge:** Breast cancer discharge is typically bloody, clear, or pink, often from a single breast, occurring spontaneously

Adult women of all ages are encouraged to perform breast self-exams at least once a month. *For women still menstruating, a breast self-exam should be performed a few days after her period ends. For those who are post-menopausal, a breast self-exam should be performed on the same day of each month, such as the 1st or 15th day of the month.*

Risk Factors[18]

Risk Factor	Risk Signal	Notes/Guidance
Female Sex	Relative Risk: ~100x	Biological sex remains the primary risk driver. Universal screening (Mammography) typically commences at age 40 for average-risk individuals

Risk Factor	Risk Signal	Notes/Guidance
BRCA1/2 Mutations	Absolute Risk: 45%–72%	Mutations severely impair DNA repair. Triggers high-intensity surveillance (annual MRI + Mammogram) and consideration of prophylactic surgery
Family History: Multiple Cancers	Relative Risk: 3.0x–4.0x	Defined as ≥2 close relatives (one diagnosed <50) or ≥3 relatives at any age. Indicates a potential autosomal dominant inheritance pattern
Ovarian Cancer Link	Relative Risk: ~2.0x–4.0x	Ovarian cancer in a 1st-degree relative is a potent "proxy" for BRCA mutations. Any family history of ovarian cancer warrants a genetic referral
Male Breast Cancer	High Risk Indicator	Because male breast cancer is statistically rare (~2,800 cases in 2025), a single instance in a family tree is a major "red flag" for hereditary syndromes
Aggressive/Other Cancers	Elevated Risk	Relatives with triple-negative breast, pancreatic, or high-grade prostate cancer suggest a shared genetic "root" (e.g., HBOC syndrome)
Bilateral Breast Cancer	Relative Risk: ~3.0x	Cancer in both breasts suggests a high biological "substrate" or predisposition rather than a sporadic, environmental event
Histologic History (DCIS)	Relative Risk: 8.0x–10.0x	Stage 0 disease. While non-invasive, it indicates a highly primed environment for future invasive malignancy in either breast
Dense Breast Tissue	Relative Risk: 1.2x–2.0x	Dense tissue masks tumors on 2D mammography (the "snowstorm" effect). Requires supplemental screening like Abbreviated MRI or Ultrasound
Receptor Status	High Recurrence Risk	HER2+ and Triple-Negative (ER-/PR-/HER2-) behave more aggressively and require systemic chemotherapy or targeted ADCs
Tumor Grade (Grade 3)	Aggressive Progression	Poorly differentiated cells indicate high mitotic activity; these tumors are more likely to grow and metastasize rapidly
Nodal Involvement	Strongest Prognostic Factor	Axillary metastasis indicates the cancer has accessed the lymphatic system. Critically dictates the "Stage" (e.g., Stage II vs. III)
Prior Radiation/ Lymphedema	Absolute Risk: Rare/Fatal	Radiation (for prior Hodgkin's) or chronic lymphedema can trigger secondary Angiosarcomas 5–10 years post-exposure
Textured Implants	Absolute Risk: Rare	Associated with BIA-ALCL (a T-cell lymphoma of the capsule/fluid), not traditional adenocarcinoma of the breast tissue
Substance Use (Alcohol)	RR: 1.07x per 10g/day	Risk increases linearly (~7% per drink). Alcohol elevates serum estrogen and causes direct DNA damage via acetaldehyde
Substance Use (Nicotine)	High Synergistic Risk	While inconsistent individually, nicotine acts as a "multiplier" for alcohol, significantly increasing systemic oxidative stress and mutation rates

Abbreviations: ADC: Antibody-drug conjugate, BIA-ALCL: Breast implant-associated anaplastic large cell lymphoma, DCIS: Ductal carcinoma in situ, ER/PR/HER2: Estrogen/Progesterone/Human epidermal growth factor receptors, HBOC: Hereditary Breast and Ovarian Cancer syndrome, IDC: Invasive ductal carcinoma, LN: Lymph node, MRI: Magnetic resonance imaging, TNBC: Triple-negative breast cancer

Red Flags - Urgent Action[19,20]

High-Risk Pathologic Red Flags

Pathology reports may identify specific features that signal a more aggressive or complex disease state:

- **Invasive Cells:** The definitive red flag is the presence of invasive cancer cells that have broken through the basement membrane into the mammary stroma → **Transition from "Screening" to "Staging."** Requires a Core Needle Biopsy (if not already done) and systemic staging (CT/PET or Bone Scan) to rule out distant metastasis before definitive surgery
- **HER2-Positivity:** Overexpression of the HER2 protein (IHC 3+ or FISH ratio ≥2.0), which indicates a more aggressive biological subtype → **Initiate HER2-Targeted Therapy (**e.g., Trastuzumab/Pertuzumab). In 2026, many HER2+ patients receive Neoadjuvant Therapy (chemo before surgery) to shrink the tumor and assess response
- **High Grade:** A Grade 3 designation, indicating poorly differentiated cells that are likely to grow and spread rapidly → **Accelerated treatment timeline.** Grade 3 tumors have a high mitotic rate; surgery or chemotherapy should typically commence within 2–4 weeks of diagnosis to prevent rapid interval growth
- **Triple-Negative Status:** Tumors that lack ER, PR, and HER2 receptors, which often behave aggressively and have fewer targeted treatment options → **Referral for Genetic Testing (BRCA1/2) regardless of age.** Treatment usually involves aggressive chemotherapy + Immunotherapy (e.g., Pembrolizumab) due to the lack of hormonal targets
- **Multicentric Disease:** The presence of multiple tumor areas in different quadrants of the breast, which may preclude breast-conserving surgery → **Surgical consultation for mastectomy.** Because tumors are in different areas of the breast, breast-conserving surgery (Lumpectomy) is often technically impossible or oncologically unsafe
- **Inflammatory Breast Cancer:** Skin/Lymph Changes → **EMERGENT Oncology Referral.** IBC is a clinical diagnosis (T4d). Do not wait for antibiotics to work if mastitis is suspected but not improving. Treat with "Chemotherapy First" (Neoadjuvant), then surgery, then radiation. Signs to look for:
  - Swelling (edema) of the skin of the breast
  - Redness involving more than one-third of the breast
  - Pitting or thickening of the skin of the breast so that it may look and feel like an orange peel
  - A retracted or inverted nipple
  - One breast looking larger than the other because of swelling
  - One breast feeling warmer and heavier than the other
  - A breast that may be tender, painful, or itchy
  - Swelling of the lymph nodes under the arms or near the collarbone

Systemic and Metastatic Red Flags

For patients with known or suspected breast cancer, certain signs may indicate the disease has spread (Metastasis). In this case, an urgent consult with a physician is needed.

- **Fixed Axillary Nodes (N2):** Lymph nodes that feel "matted" or fixed to other structures during a physical exam Indicates extracapsular extension → Requires **Axillary Ultrasound** and ultrasound-guided FNA/Core Biopsy. Initiate systemic chemotherapy (Neoadjuvant) to "downstage" the axilla before attempting surgery
- **Bone Pain:** Persistent, deep aching (especially in the spine or ribs) that is often worse at night → **Highly suggestive of osseous metastasis.** Order a **Whole-Body Bone Scan** or **PET/CT**. If spinal pain is present, urgent **MRI of the Spine** is required to rule out imminent cord compression
- **Neurological Symptoms:** New-onset headaches or motor deficits, which may signal secondary neoplasms in the brain (C79.31) → **Suspected Brain Metastasis (C79.31)**. Immediate MRI of the Brain with Contrast. If intracranial pressure is elevated, initiate high-dose corticosteroids (Dexamethasone) and consult Radiation Oncology
- **Jaundice or Elevated LFTs (Liver Function Tests):** Signs of liver involvement (C78.7), such as yellowing of the skin or abnormal liver function tests → **Suspected Hepatic Metastasis** (**C78.7**). Order a **CT Abdomen/Pelvis with IV Contrast** or Liver MRI. Assess for biliary obstruction; may require IR-guided biopsy for genomic re-profiling

Clinical Red Flags

- **Inflammatory Breast Cancer (IBC) vs. Mastitis:** IBC is a clinical diagnosis characterized by the sudden onset of **Peau d'orange** (skin thickening/pitting) and erythema involving >1/3 of the breast → **EMERGENT Oncology Referral.** If symptoms persist after **7–10 days** of antibiotics, perform a **Skin Punch Biopsy** to identify dermal lymphatic invasion. Treat with neoadjuvant chemotherapy *before* surgery
- **Isolated Axillary Lymphadenopathy:** Enlarged axillary node with a negative breast exam and mammogramWhen a patient presents with an enlarged axillary node but a negative breast exam/mammogram → Evaluation must include a thorough skin check (melanoma) and potentially a **Breast MRI** to detect an "occult" primary breast cancer that is too small for mammography
- **The Young Patient (<30 Years):** New breast mass in a patient with high parenchymal density → **Ultrasound** is the primary imaging modality. Mammography is reserved for cases with suspicious US findings

Diagnostic Thresholds

The definitive diagnostic threshold for breast cancer is the **histopathologic confirmation of invasive cancer cells** obtained through a tissue biopsy. Clinicians use a combination of imaging, physical examination, and cellular analysis to meet specific diagnostic and staging criteria. **See screening/diagnostic workup section**.

Clues to Dig Deeper

- **Spontaneous Nipple Discharge:** Unilateral, single-duct discharge is highly suspicious. Order a Diagnostic Ultrasound and Sub-areolar Mammogram to rule out intraductal papilloma or DCIS
- **New Nipple Inversion:** If the nipple cannot be everted, it suggests a retroareolar tumor pulling on the Cooper's ligaments. Perform targeted Retroareolar Ultrasound
- **Unexplained Weight Loss (Systemic Cachexia):** Loss of >10% body weight without effort

Highly suggestive of Metastatic (Stage IV) disease. Order a PET/CT to evaluate for distant organ involvement

- **Persistent "Mastitis":** If erythema persists >7 days despite antibiotics. Perform a Skin Punch Biopsy to rule out Inflammatory Breast Cancer (IBC)
- **Palpable Supraclavicular Node:** A palpable node above the collarbone suggests advanced lymphatic bypass of the axilla. Requires FNA/Biopsy and systemic staging (Chest CT)
- **"Numb Chin" Syndrome (Mental Nerve Neuropathy):** Rare but specific. New chin numbness in a breast cancer patient can signal base of skull metastasis or systemic spread. Order MRI of the Brain/Skull Base

Common Oversights[5,21]

1. Clinical and Physical Oversights

- **Misinterpreting Nipple Changes:** Overlooking scaly or ulcerated nipple lesions as simple dermatitis rather than potential Paget disease
- **Reliability of Palpation:** Relying solely on physical examination to assess axillary lymph nodes; clinical palpation has a low negative predictive value (50% to 60%), meaning many non-palpable nodes actually harbor metastasis
- **Dismissing Localized Pain:** Assuming breast cancer is always painless, when persistent localized pain can occasionally be an early red flag

2. Imaging and Local Extent Oversights

- **Underestimating Tumor Size:** Failing to recognize that mammographic microcalcifications frequently underestimate the actual pathologic extent of the malignancy, sometimes by up to 2 cm
- **Dense Breast Tissue Limitations:** Overlooking the fact that dense breast tissue can obscure tumor borders on a mammogram, necessitating supplemental imaging like Breast MRI or Contrast-Enhanced Mammography
- **Misidentifying Multifocal Disease:** Incorrectly interpreting several groups of microcalcifications separated by normal tissue as separate tumors, when they may actually represent a single, contiguous tumor that is only partially calcified

3. Pathologic and Staging Oversights

- **Anatomic vs. Prognostic Staging:** Assigning a stage based purely on anatomy (TNM) without incorporating the Clinical Prognostic Stage, which accounts for Grade, ER, PR, and HER2 status
- **The "y" Prefix:** Neglecting to use the ypTNM designation for patients who have undergone neoadjuvant therapy, which is essential for accurately documenting the final pathologic stage after treatment
- **Missing Microinvasion:** Failing to distinguish between pure DCIS and DCIS with microinvasion ($\leq$1 mm), which changes the diagnosis from a precancerous lesion to invasive cancer

Abbreviations: ER: Estrogen receptor, PR: Progesterone receptor, HER2: Human Epidermal Growth Factor 2, DCIS, Ductal Carcinoma In Situ

4. Systemic Workup Oversights

- **Over-Staging Low-Risk Patients:** Routinely ordering systemic imaging (CT/PET) for Stage I or II patients who are asymptomatic, which is not recommended
- **Under-Staging High-Risk Patients:** Failing to perform a distant metastatic workup for patients with locally advanced disease, such as those with T3 or greater or N2/N3 nodal status
- **Intramammary Node Significance:** Overlooking the presence of intramammary lymph nodes; if these contain metastasis, they confer a worse prognosis even if axillary nodes appear negative

Abbreviations: CT: computed tomography, PET: positron emission tomography

Key Differentials[22]

Differential Diagnosis: Breast Mass & Axillary Lymphadenopathy

Category	Breast Mass Differentials	Axillary Lymphadenopathy (ALN) Differentials
Malignant	Invasive Carcinoma (IDC/ILC): Firm, non-tender, fixed mass	Metastatic Breast Cancer: Most common cause of malignant ALN
	DCIS: Rarely palpable; usually microcalcifications	Lymphoma/Leukemia: Often bilateral; associated with "B-symptoms" (fever, night sweats)
	Phyllodes Tumor: Rapidly growing, large, mobile mass	Metastatic non-breast: Melanoma, lung, or thyroid primaries
Infectious	Mastitis: Erythema, pain, systemic fever	Cat Scratch Disease: Bartonella henselae infection
	Breast Abscess: Fluctuant, tender mass	Lymphadenitis: Suppurative infection of the nodes
	Fat Necrosis: Post-traumatic; firm, mimics cancer	Tuberculosis: Granulomatous nodal involvement
Benign / Reactive	Fibroadenoma: Rubbery, "breast mouse" mobility	Reactive Hyperplasia: Viral illness or local skin infection
	Breast Cyst: Smooth, fluctuant; fluctuates with menses	Silicone Lymphadenopathy: Leakage from breast implants
	Galactocele: Milk-retention cyst in lactating women	Post-Vaccination: Common transient finding (e.g., post-COVID/Flu)

Abbreviations: IDC, Infiltrating Ductal Carcinoma; ILC, Infiltrating Lobular Carcinoma; DCIS, Ductal Carcinoma In Situ; IBC, Inflammatory Breast Cancer; ALN, Axillary Lymph Node

Comorbidity Screening[23–25]

1. Cardiovascular Screening (Cardio-Oncology)

Specific treatments significantly elevate the risk of heart failure, left ventricular dysfunction, and vascular toxicities:

- **Anthracyclines:** Chemotherapies like doxorubicin (Adriamycin) or epirubicin (Ellence) are associated with dose-dependent cardiotoxicity
- **HER2-Targeted Therapies:** Monoclonal antibodies such as trastuzumab (Herceptin) and pertuzumab (Perjeta) can cause reversible myocardial changes
- **Radiation Therapy:** High-dose radiation (≥ 30 Gy) or left-sided chest radiation where the heart is in the treatment field increases long-term risk for CAD and valvular disease
- **Screening Metric:** Baseline and serial Echocardiograms or MUGA scans to monitor Left Ventricular Ejection Fraction (LVEF)
- **Documentation:** Clear notation of the LVEF percentage and any initiation of ACE inhibitors or beta-blockers for heart strain

Screening Phase	Frequency & Requirement	Metric/Test
Baseline	Before starting any cardiotoxic therapy	LVEF assessment via Echocardiogram (first-line) or MUGA scan
During Treatment	Every 3 months for patients on HER2-targeted therapy	Serial Echocardiograms with strain imaging (GLS) to detect early dysfunction
Post-Treatment	Every 6 months for 2 years after anti-HER2 therapy; then periodic surveillance	Echocardiogram, EKG, and serum biomarkers like NT-proBNP or Troponin

Abbreviations: ACEI: angiotensin-converting enzyme inhibitor , Baseline: initial assessment before cardiotoxic therapy , cTn: cardiac troponin (I or T), CTRCD: cancer therapeutics-related cardiac dysfunction , Echo: echocardiogram , EKG/ECG: electrocardiogram, GLS: global longitudinal strain , HER2: human epidermal growth factor receptor 2 , LVEF: left ventricular ejection fraction, MUGA: multiple-gated acquisition scan , NT-proBNP: N-terminal pro-B-type natriuretic peptide

2. Bone Health & Metabolic Screening

Patients on Aromatase Inhibitors (AIs) or those undergoing chemically induced menopause are at high risk for accelerated bone loss.

- **Screening Metric:** Baseline and biennial DXA Scans to monitor for osteoporosis
- **Metabolic Check:** Regular monitoring of fasting glucose and lipid panels, as some hormonal therapies can exacerbate diabetes or hyperlipidemia

3. Psychological & Cognitive Screening

The "whole-person" approach in 2026 mandates screening for the mental toll of chronic treatment.

- **Distress Thermometer:** An annual or per-cycle screening tool used to identify mental health concerns
  - PHQ-9 (Patient Health Questionnaire-9) for depression
  - GAD-7 (Generalized Anxiety Disorder-7) for anxiety
- **Cognitive Assessment:** Screening for "chemo-brain" or cognitive decline, particularly in older patients or those on long-term endocrine therapy, often using the MoCA (Montreal Cognitive Assessment)

Staging/Severity Matrix[26]

The **AJCC 8th Edition** has superseded the purely **Anatomic Staging** model by introducing **Prognostic Staging** as the primary standard for clinical care. This transition reflects the integration of **biological determinants**—specifically **histologic grade**, **hormone receptor (ER/PR) expression**, and **HER2/neu amplification**—with traditional **TNM descriptors** (Tumor size, Nodal status, Metastasis). **See appendix for more details.**

Key Understanding: Anatomic vs. Prognostic Staging

Under the AJCC 8th Edition, the biological profile (i.e. tumour markers) can significantly "downstage" a patient's prognosis compared to their anatomic stage (based on TMN). Clinical staging estimates breast cancer stage before treatment using exams and imaging (like mammograms, ultrasounds, biopsies), while pathologic staging, determined after surgery, provides a more precise stage by examining the actual removed tumor and lymph nodes.

Anatomic vs Prognostic stage:

- **Anatomic Stage (aStage):** "How big is it and where has it spread?". It focuses on the anatomy of the cancer, often used for staging before molecular markers are known
- **Prognostic Stage (pStage):** "How is the cancer likely to behave?". It acts as a more refined, personalized staging system (e.g., a small, aggressive HER2-positive tumor might be anatomic Stage I but a higher, more severe prognostic stage)
- **Components:** Anatomic (T, N, M) vs. Prognostic (T, N, M, ER/PR, HER2, Grade)
  - **See appendix for TMN chart**
- **Accuracy:** Prognostic stage often provides a more precise estimation of survival outcomes compared to anatomic stage alone

Type	When Determined	What It Uses	Why It Matters
Clinical Stage (prognostic)	Before treatment	Exam + imaging + biopsy	Guides initial therapy decisions
Pathologic Stage (prognostic)	After surgery	Surgical tumor & lymph node analysis	More precise prognosis

Prognostic stage groups AJCC UICC 8th edition

Example 1: If the cancer size is between 2 and 5 cm (T2) but it has not spread to the nearby lymph nodes (N0) or to distant organs (M0) AND is:

- Grade 3
- HER2 negative
- ER positive
- PR positive

The cancer stage is IB (Small tumors with minimal or no nodal involvement).

Example 2: If the cancer is larger than 5 cm (T3) and has spread to 4 to 9 lymph nodes under the arm or to any internal mammary lymph nodes (N2) but not to distant organs (M0) AND is:

- Grade 2
- HER2 positive
- ER positive
- PR positive

The cancer stage is IB.

3. MEAT DOCUMENTATION ESSENTIALS

The patient case described below is a post-menopausal female with high-risk early-stage breast cancer (Stage IIA) who has completed her primary surgical/systemic treatment and is now in the Adjuvant Survivorship Phase.

MONITOR: "Interval mammo/DBT (02/2026) shows stable architectural distortion at biopsy site; CEA/CA 15-3 stable; bone scan negative for metastasis; TAM adherence confirmed via pharmacy fill history"

EVALUATE: "Physical exam: 2cm surgical scar RLQ well-healed, no palpable axillary LN; DEXA T-score -2.1 (osteopenia secondary to AI therapy); LVEF 55% per TTE (baseline for Herceptin)"

ASSESS: "Stage IIA (T2N0M0) ER/PR+, HER2- IDC of the right breast; currently stable on adjuvant endocrine therapy but complicated by AI-induced arthralgia and osteopenia"

TREAT: "Continue Letrozole 2.5mg daily; initiated Zoledronic acid for bone protection; referred to Physical Therapy for early lymphedema management; scheduled 6-month surveillance imaging"

Clinical Documentation Elements

Reflect phenotype, severity, and longitudinal management.

Link complications to the underlying malignancy: Connect a secondary complication directly to the primary malignancy for a more robust clinical picture. "Lymphedema of the right upper extremity (I89.0) due to previous axillary lymph node dissection for R-breast adenocarcinoma."

Include current objective data: Use objective, dated evidence to prove the cancer is an active, monitored condition rather than a historical one. "Latest PET/CT scan [date] shows decreased FDG (Fluorodeoxyglucose) avidity in the primary L-UOQ (Left Upper Outer Quadrant) lesion, consistent with positive response to current Neoadjuvant therapy."

Specify malignancy precisely: Provide the exact anatomical site, TNM staging, and molecular markers required for high-specificity ICD-10 coding. "Invasive Ductal Carcinoma of the Right Lower-Outer Quadrant (C50.411), Stage IIIA (T2, N2, M0); ER/PR+, HER2-negative."

Document chronicity: Demonstrate ongoing active management of a chronic condition, preventing the downcoding to "Patient in Year 4 of a planned 10-year course of Tamoxifen for ER+ breast cancer; managing treatment-induced vasomotor symptoms (hot flashes).”

Reframing Common Documentation Shortcuts

Instead of...	Document...	Why this supports clarity
"History of breast cancer"	"Active Invasive Ductal Carcinoma (C50.411) of the R-UOQ; currently undergoing adjuvant Chemotherapy (cycles 3 of 6)"	**Clarifies disease status.** Distinguishes active malignancy from past history and reflects ongoing treatment.
"Cancer stable"	"Stage IIIA (T3, N1, M0) Breast Cancer; PET scan [Date] shows no new metabolic activity in axillary nodes"	**Specify stage and objective data.** TNM staging and dated imaging provide a precise clinical snapshot of disease status
"Bone pain"	"Pathologic fracture of L2 vertebra (M84.58) secondary to Metastatic Breast Cancer (C78.7); palliative radiation initiated"	**Link complications to the underlying malignancy.** Connecting symptoms to the causal condition improves the accuracy of the clinical record
"Follow up oncology"	"Continuing Anastrozole 1mg daily for ER+ Breast Malignancy; managing arthralgia side effects; DEXA [Date] monitored for bone density"	**Demonstrates ongoing care management.** Shows active monitoring of therapy and associated risks
"Lump in breast"	"Malignant neoplasm of the nipple and areola, left female breast (C50.012). Biopsy [Date] confirmed HER2+ status"	**Specify site and tumor biology.** Anatomical location and receptor status provide clinically meaningful detail for treatment planning

Abbreviations: AC: active, Adj: adjuvant, AI: aromatase inhibitor (e.g., Anastrozole), ALND: axillary lymph node dissection, BC: breast cancer, Bx: biopsy, Chemo: chemotherapy, DEXA: dual-energy x-ray absorptiometry, ER+: estrogen receptor positive, HER2+: human epidermal growth factor receptor 2 positive, IDC: invasive ductal carcinoma, L: left, MBC: metastatic breast cancer, METS: metastasis, PET: positron emission tomography, R: right, RT: radiation therapy, TNM: tumor, node, metastasis staging, UOQ: upper outer quadrant

4. TREATMENT & REFERRAL QUICK GUIDE

Therapy Escalation Criteria[27–29]

Early Stage: Treatment of stage 0 breast cancer (ductal carcinoma in situ)

Ductal carcinoma in situ (DCIS) is a condition where abnormal cells form in the lining of the milk ducts but have not spread. It's not cancer, but it may develop into invasive cancer. Treatment of DCIS may include lumpectomy with radiation therapy, mastectomy with or without radiation, and hormone therapy if biomarker testing suggests it may be helpful.

Early Stage: Treatment of stages I to III breast cancer

Treatment of early-stage breast cancer, which includes stages I, IIA, and some stage IIB breast cancers, usually begins with surgery to remove the cancer. Surgery is often followed by additional therapy. If the tumor is large, chemotherapy or targeted therapy may be given before surgery to make the tumor smaller and easier to remove.

Treatment of locally advanced breast cancer, which includes some stage IIB breast cancers and stages IIIA, IIIB, and IIIC, often begins with chemotherapy, followed by surgery and radiation.

Treatment of stages I to III breast cancer may include:

1. **Surgery:** Lumpectomy (breast-conserving surgery) is often used, but mastectomy may be recommended if the tumor is large or cancer is found in multiple areas of the breast or chest. The surgeon may also remove the underarm lymph node closest to the tumor in a procedure called sentinel lymph node biopsy. Learn more about Breast Cancer Surgery and Sentinel Lymph Node Biopsy
2. **Radiation therapy:** After surgery, radiation therapy to the breast or the chest wall where the breast was removed to reduce the chance of breast cancer returning in the breast or the chest wall
3. **Chemotherapy:** Chemotherapy will likely be used if the tumor is high grade, in the lymph nodes, HER2-positive, or triple-negative. Whether chemotherapy is given before or after surgery depends on the size and location of the tumor and other factors
4. **Hormone therapy:** If the cancer tests positive for estrogen receptor and/or progesterone receptor, or when the hormone receptor status of the cancer is unknown, hormone/endocrine therapy may be used. Hormone therapy for breast cancer may begin before or after surgery. If the patient is premenopausal, they might also have treatment to stop the ovaries from making hormones
5. **Immunotherapy.** This cancer treatment is only used to treat triple-negative breast cancer
6. **Targeted therapy**: If biomarker tests suggest that the cancer is HER2-positive, hormone-receptor positive, or has a BRCA1 or BRCA2 mutation, the patient may receive targeted therapy before or after surgery

See appendix for more details on the different types of treatment.

Common Treatment Pathway for Early Breast Cancer



Metastatic Breast Cancer Treatment

Breast cancer that has spread beyond the breast, chest wall, or nearby lymph nodes is called metastatic breast cancer. Systemic treatments are selected based on the tumor's molecular profile and genetic drivers, which may include hormone therapy, immunotherapy, chemotherapy, targeted therapy, or antibody-drug conjugates. In the metastatic setting, local interventions shift from curative intent to symptom palliation and structural stability. Radiation therapy is primarily utilized to manage complications from metastases, such as palliating bone pain, treating brain metastases, or preventing spinal cord compression. Palliative surgery is reserved for mechanical issues rather than primary tumor eradication. Examples include internal fixation of pathological fractures or resection of symptomatic CNS lesions.

Modality	Key Agents	Clinical Indications
Hormone Therapy	Aromatase Inhibitors (Letrozole), SERDs (Fulvestrant)	First-line for HR+ (ER+/PR+) disease

Modality	Key Agents	Clinical Indications
Targeted Therapy	CDK4/6 inhibitors (Palbociclib), HER2-targeted (Trastuzumab), PARP inhibitors	Blocks specific growth pathways (e.g., HER2, BRCA1/2)
Chemotherapy	Taxanes (Paclitaxel), Anthracyclines, Capecitabine	Cytotoxic treatment for high-burden or Triple-Negative (TNBC) disease
Immunotherapy	Checkpoint inhibitors (Pembrolizumab)	Indicated for high-mutation loads or PD-L1+ TNBC
Antibody-Drug Conjugates (ADCs)	Trastuzumab deruxtecan (Enhertu), Sacituzumab govitecan	"Smart bombs" delivering potent cytotoxins directly to cells

Abbreviations: ET, Endocrine Therapy; AI, Aromatase Inhibitor; SERD, Selective Estrogen Receptor Downregulator; HR, Hormone Receptor; ER/PR, Estrogen/Progesterone Receptor; CDK4/6i, Cyclin-Dependent Kinase 4/6 Inhibitor; HER2, Human Epidermal Growth Factor Receptor 2; PARP, Poly (ADP-ribose) Polymerase; BRCA1/2, BReast CAncer gene 1 or 2; CTX, Chemotherapy; TNBC, Triple-Negative Breast Cancer; IO, Immunotherapy; CPI, Checkpoint Inhibitor; PD-L1, Programmed Death-Ligand 1; ADC, Antibody-Drug Conjugate; T-DXd, Trastuzumab deruxtecan



*CT, Chemotherapy; HT, Hormone therapy.

See Appendix for more information treatments.

Chemotherapy Strategy: Sequential vs. Combination

- **Sequential Single-Agent (Preferred):** For most patients, using one chemotherapy drug at a time in a sequence is the preferred approach.
  - **Benefits:** It provides symptom relief (palliation) with significantly fewer side effects
  - **Survival:** No studies have shown that giving multiple chemo drugs at once improves overall survival compared to giving them one after another
- **Combination Chemotherapy:** This is reserved for patients with a high disease burden or rapidly progressing disease where "impending organ dysfunction" is a concern. The goal here is a faster response, despite the higher risk of toxicity

Combining Systemic Treatments[30]

- **Chemo + Endocrine Therapy:** Generally **not recommended** to be given concurrently. Trials have failed to show a survival benefit, and the combination increases side effects
- **Successful Combinations:**
  - **HER2-Directed Therapy:** Can be safely and effectively combined with chemotherapy or endocrine therapy
  - **Endocrine Therapy:** Is standardly combined with targeted agents like **CDK 4/6 inhibitors**, mTOR inhibitors, or PI3K inhibitors

Local and Supportive Treatments[27]

- **Local Management:** While systemic therapy (drugs) is the primary treatment, local options like **surgery or radiation** are used to:
  - Manage symptoms (palliation)
  - Prevent complications at specific metastatic sites
  - *Note:* The survival benefit of removing the primary tumor in a metastatic setting is still a subject of debate and conflicting data
- **Bone Health (Osteoclast Inhibitors):** All patients with bone metastases should receive bone-modifying agents (like **bisphosphonates** or **RANK ligand inhibitors**)
  - **Purpose:** These significantly reduce the risk of "skeletal-related events," such as fractures, spinal cord compression, and the need for bone surgery

Approach	Recommendation	Key Rationale
Chemotherapy	Single-agent, sequential	Lower toxicity; no survival difference vs. combination
HER2+ Disease	HER2-targeted + Partner drug	Demonstrated survival improvement
HR+ Disease	Endocrine + Targeted agent	Standard of care; delays the need for chemo
Bone Metastases	Osteoclast inhibitors	Prevents fractures and bone-related pain

Abbreviations: AI, Aromatase Inhibitor; CDK 4/6, Cyclin-Dependent Kinase 4 and 6; CT, Chemotherapy; ET, Endocrine Therapy; HER2+, Human Epidermal Growth Factor Receptor 2 Positive; HR+, Hormone Receptor Positive; OS, Overall Survival; QoL, Quality of Life; SRE, Skeletal-Related Event

Value-based Approach to Treatment[31–35]

AAVBC supports an approach to breast cancer care grounded in evidence and shared decision-making. A value based care strategy that prioritizes each person's survival, quality of life, and treatment experience. When care is aligned with evidence and tailored to individual clinical needs, it avoids unnecessary harm and supports sustainable, equitable use of available therapies.

1. Early-Stage Breast Cancer

The goal in early-stage care is cure, with treatment calibrated to each person's individual risk profile. Evidence-based tools — including genomic assays, updated surgical standards, and shorter radiation

schedules — allow care teams and patients to make decisions that reduce unnecessary burden without compromising outcomes.

- **Precision De-escalation (Genomics):** Utilize assays like **Oncotype DX** or **MammaPrint** to identify patients with low recurrence scores and who can safely omit chemotherapy. This can spare patients from toxicity while lowering costs by up to~$20,000–$30,000 per avoided regimen
- **Axillary Management:** Moving from full axillary dissection to sentinel lymph node biopsy — or, in carefully selected patients, omitting nodal surgery altogether — substantially reduces the risk of lymphedema and long-term arm dysfunction. This shift in surgical approach, supported by SOUND and CALGB 9343 trial evidence, reflects a meaningful improvement in the care experience for many patients, with associated reductions in recovery time and downstream care needs
- **Hypofractionated Radiation:** Utilizing "Fast-Forward" protocols (5 days of radiation vs. 3–5 weeks). This offers equal clinical outcomes with significantly lower patient travel costs and facility resource use
- **Biosimilar Utilization:** Adoption of biosimilars for **Trastuzumab (Herceptin)** in HER2+ cases to reduce drug spend by 30–50% without compromising efficacy
- **Accelerated Partial Breast Irradiation (APBI):** For appropriately selected low-risk patients, APBI targets only the tumor bed. It can save roughly **$2,591 per patient** when including indirect costs like travel and lost work time, while providing excellent quality-adjusted life years (QALYs)
- **Intraoperative Radiotherapy (IORT):** For elderly patients or those with significant travel barriers, intraoperative radiotherapy may reduce the burden associated with multi-week external beam courses. Evidence from TARGIT-A supports its use in carefully selected, low-risk patients, though longer-term local control data remain under evaluation and it is not yet endorsed as a standard alternative across guidelines

2. Late-Stage (Metastatic) Breast Cancer

In the metastatic setting, value is defined by **prolonging life** and **maximizing "well years"** (Quality of Life) while managing the escalating costs of therapy.

- **Biomarker-Driven Therapy:** Adherence to "Next-Generation Sequencing" (NGS) to find actionable targets like *PIK3CA*, *ESR1*, or *BRCA1/2*. This alters the trajectory of the disease by prioritizing biological compatibility over broad-spectrum cell destruction. Targeted agents spare healthy rapidly-dividing cells (unlike chemotherapy, helping reduce toxicity and extend progression free survival
- **The ADC "Value Flip":** Utilizing Antibody-Drug Conjugates (ADCs) like **Enhertu (T-DXd)**. While the upfront cost is very high (~$15,000+/month), the value is found in significantly longer progression-free survival (PFS), which prevents costly emergency department (ED) visits and hospitalizations due to disease flare-ups
- **PROMs (Patient-Reported Outcome Measures):** Structured collection of patient-reported outcomes — including real-time symptom tracking via digital tools — has been associated with reduced emergency visits, fewer hospitalizations, and improved survival in randomized trials
- **Early Palliative Integration:** Introducing palliative care at the time of a stage IV diagnosis, rather than reserving it for the final weeks of life, is associated with improved quality of life, better symptom management, and in some studies, longer survival. It also supports patients and families

in clarifying their goals of care early, which tends to align treatment decisions more closely with what matters most to each person

Monitoring Therapy[36–38]

1. Clinical Assessment (The Patient's Experience)

The most direct way to monitor success is through history and physical examination.

- **Symptom Relief:** If a patient feels significantly better—less pain, more energy, or improved breathing—the treatment is likely working, even if imaging hasn't been performed yet
- **Physical Exam:** For accessible disease, such as chest wall nodules or swollen lymph nodes, a doctor can manually track shrinkage

2. Tumor Markers (Surveillance & Metastatic Monitoring)

Blood tests like **cancer antigen (CA) 15-3, CA 27.29, and carcinoembryonic antigen (CEA)** can help track the disease, especially when the cancer is not easily seen on a physical exam. Serum tumor markers are primarily used to track response to treatment in **metastatic (Stage IV)** disease. They are generally *not* recommended for routine surveillance in early-stage (Stage I-III) patients because they can cause false positives.

CA 15-3 & CA 27.29: Most common breast-specific serum markers. A rising trend often indicates disease progression

- Medical Necessity: CA 15-3 or CA 27.29 may be used to monitor response to therapy or evaluate for residual disease in patients with a confirmed diagnosis of breast cancer
    - Medicare covers **either marker for monitoring**, but **not both simultaneously** for the same clinical purpose
    - These assays are not indicated for screening or for evaluation of patients with suspected malignancy without a confirmed diagnosis
- **CEA (Carcinoembryonic Antigen):** A general marker used alongside CA 15-3 to monitor metastatic spread
- **When to use:** ASCO suggests starting with CA 15-3 or CA 27.29; If not elevated, CEA is used
- **The "Flare" Phenomenon:** It is common for markers to temporarily rise (spike) in the first 1–2 months of a new treatment. This phenomenon likely represents **pseudoprogression** or a **transient surge in serum tumor markers** secondary to **cytotherapeutic-induced cytolysis**, and is not pathognomonic of treatment failure
- **Limitations:** Markers can be falsely elevated by liver dysfunction, B12 deficiency, or anemia. A rise in markers alone, without other evidence, is usually not enough to change a treatment plan. While markers like CA 15-3 and CEA are approved to aid in monitoring, they are not recommended for sole use in detecting recurrence due to a lack of sensitivity (they may not rise even if cancer is present) and specificity (they may rise due to other causes)

3. Radiographic Studies (Imaging)

Scans are typically performed every 2 to 4 months to visualize changes in the tumor.

- **Modalities:** CT, MRI, and Bone Scans are standard. PET scans can sometimes be used
  - **Early-Stage (Stages I, II, Operable III):** PET scans are not recommended for routine surveillance after curative treatment. Standard follow-up typically involves a physical exam every 3–6 months for the first three years and an annual mammogram
  - **Advanced or Metastatic Disease (Stage IV):** For patients with metastatic breast cancer (MBC), PET/CT scans may be used every 2–4 months (or every 2–4 cycles of chemotherapy) to evaluate how well the treatment is working
  - **Locally Advanced (Stage III):** A PET scan may be used at the time of diagnosis to check for distant spread if other tests are inconclusive
- **The "Healing Flare":** On a bone scan, a responding tumor may actually look "brighter" or more active as the bone begins to heal and rebuild. This can last for several months and can be mistaken for cancer growth

4. Advanced Testing (Not Routine)[37]

While technology is advancing, some methods are not yet recommended for making treatment decisions:

- **Circulating Tumor Cells (CTCs):** Counting cancer cells in the blood is a strong predictor of survival. However, experts do not currently recommend changing treatment based solely on these counts
- **Circulating Tumor DNA (ctDNA):** Using "liquid biopsies" to track mutations or the clearance of cancer DNA is an area of intense research but is not yet standard clinical practice

Duration of Treatment[39(p2)]

Treatment is highly individualized and typically continues until one of the following occurs:

- **Disease Progression:** The treatment is no longer keeping the cancer in check
- **Intolerable Toxicity:** Side effects become too severe to maintain a good quality of life
- **Best Response:** The maximum benefit has been achieved (in some cases, this leads to "maintenance therapy" discussions)

Defining Treatment Failure

Doctors determine if a treatment has failed by looking for specific signs of "progression." They use the **RECIST 1.1** criteria to standardize these findings:

- **Clinical Decline:** Increased symptoms, worsening physical weakness, or intolerable side effects.
- **New Disease:** The appearance of any new metastatic lesions
- **Growth of Existing Tumors:** A **20% or greater increase** in the size of measurable target lesions
- **Worsening Bone Disease:** Significant progression of non-measurable sites, like bone metastases

Non-Rx Treatment Documentation[40,41]

Physical & Rehabilitation Therapies

These focus on maintaining the body's strength and function during treatment.

- **Physical Therapy (PT):** Helps manage weakness, improve mobility, and address "cording" or range-of-motion issues following surgery or radiation
- **Lymphedema Therapy:** Specialized massage (manual lymphatic drainage) and compression garments to manage swelling in the arm or chest
- **Exercise:** Clinical guidelines strongly recommend moderate exercise (like walking or yoga) to reduce "cancer-related fatigue," improve mood, and maintain bone density

Integrative & Supportive Therapies

These are used alongside medical care to improve well-being and manage side effects.

- **Acupuncture:** Often used to help manage chemotherapy-induced nausea, hot flashes from hormone therapy, and joint pain
- **Nutritional Counseling:** Working with an oncology dietitian to manage appetite changes, weight loss, or digestive issues caused by treatment
- **Mind-Body Practices:**
  - **Meditation and Mindfulness:** To reduce the anxiety and stress associated with chronic illness
  - **Cognitive Behavioral Therapy (CBT):** Can be highly effective for managing "chemo brain" (cognitive fog) and insomnia

Palliative Care (Supportive Care)

It is a common misconception that palliative care is only for the end of life. In metastatic disease, a palliative care team works alongside the oncologist to:

- Manage complex pain
- Help with "advance care planning" (clarifying goals and preferences)
- Provide an extra layer of support for the emotional and spiritual toll of the disease

Follow-up Timing[31,42]

Follow-up timing for metastatic breast cancer (MBC) is not "one size fits all." Instead, it is scheduled based on the type of treatment the patient is receiving and how stable the disease is.

Here is the typical breakdown for follow-up timing:

1. Imaging and Scans (Radiographic)

The goal is to see if the tumor is shrinking, stable, or growing.

- **Standard Timing:** Every 2 to 4 months
- **Earlier Scans:** If the patient develops new symptoms (like new pain, shortness of breath, or neurological changes), scans are often moved up immediately
- **Late-Stage/Stable Disease:** If the cancer has been stable for a very long time on a specific therapy, the physician may occasionally extend the gap between scans, though 3 months is the most common "gold standard"

2. Blood Work and Tumor Markers

Blood tests are usually done more frequently than scans because they are less invasive and provide a "real-time" snapshot.

- **Tumor Markers (CA 15-3, CEA):** Usually checked every 1 to 3 months, often at the start of a new treatment cycle
- **Safety Labs (CBC and Metabolic Panel):** These are often done every 1 to 4 weeks, depending on the toxicity of medication (e.g., checking white blood cell counts for patients on CDK 4/6 inhibitors or chemotherapy)

3. Clinical Exams and Appointments

- **New Treatment Initiation:** Patient should see their oncologist every 1 to 3 weeks during the first two months of a new therapy to monitor for side effects
- **Stable Treatment:** Once the patient is tolerating a therapy well, office visits usually sync with treatment cycles, typically every 3 to 4 weeks

Type of Follow-up	Typical Frequency	Purpose
CT/MRI/PET Scans	Every 8–16 weeks	To measure tumor size and look for new spots
Bone Scans	Every 3–6 months	To monitor bone metastases (less frequent than CT)
Tumor Markers	Every 4–12 weeks	To look for trends in cancer proteins
Safety Blood Work	Every 1–4 weeks	To ensure liver, kidneys, and blood counts are healthy
Physical Exam	Every 3–4 weeks	To check for new symptoms or palpable changes
Abbreviations: CT, Computed Tomography; MRI, Magnetic Resonance Imaging; PET, Positron Emission Tomography		

Important Timing Caveats

- **The "Flare" Period:** Be cautious about interpreting results in the first **4 to 8 weeks** of a new treatment. Tumor markers and bone scans can look *worse* initially while the body reacts to the treatment "killing" the cancer cells
- **Liquid Biopsies (not routine):** If using circulating tumor DNA (ctDNA) to monitor for new mutations (like *ESR1*), this is often done **serially** (every few months) or specifically when a current treatment stops working
    - **Key Clinical Note:** Circulating tumor DNA (ctDNA) liquid biopsies are not yet considered standard routine care for all breast cancer patients, but they are increasingly used in clinical

practice for managing metastatic (stage IV) disease. Liquid biopsy, which involves a blood test to analyze cancer DNA fragments, is primarily utilized to detect resistance mutations (e.g., ESR1) and guide targeted therapies

Patient Education & Adherence[43,44]

The "Red Flag" System

A vital part of education is knowing when *not* to wait for the next appointment. Patients are instructed to contact the care team immediately for:

- Fever (often defined as ≥100.4F or ≥38C)
- Uncontrolled vomiting or diarrhea that prevents hydration
- Sudden shortness of breath or new, severe pain
- Signs of an allergic reaction (rash, swelling, or difficulty swallowing)

Key Pillars of Patient Education

Education empowers patients to become active partners in their care. Essential topics include:

- **The "Why" of the Regimen:** Helping the patient understand how each drug works (e.g., "starving" the cancer of hormones vs. stopping cell division) increases the likelihood of long-term commitment
- **Proactive Side Effect Management:** Educate patients on being proactive with their medications before symptoms appear, such as for nausea or diarrhea
- **Dosing Logic and Adherence:** Provide the patient with an understanding of why their dosing and timing is appropriate for their given therapy. Some medications require specific conditions (e.g., "take with a high-fat meal" or "avoid grapefruit juice") because food and other substances can dramatically change how much medicine the body absorbs

Comorbidity Management[25,45,46]

Research indicates that over half of patients diagnosed with breast cancer have at least one other health condition. The most frequently reported include:

- **Cardiovascular & Metabolic:** Hypertension (high blood pressure), high cholesterol, and Type 2 diabetes
- **Musculoskeletal:** Arthritis and osteoporosis
- **Respiratory:** Asthma and Chronic Obstructive Pulmonary Disease (COPD)
- **Psychological:** Depression and anxiety (which are particularly prevalent in younger patients)
- **Weight-Related:** Obesity or a high Body Mass Index (BMI)

The presence of other health conditions often dictates which breast cancer treatments are safe or effective:

- **Treatment Selection:** Certain chemotherapy drugs or targeted therapies can be hard on the heart or kidneys. If a patient has pre-existing heart disease or renal failure, doctors may choose less toxic alternatives
- **Dose Adjustments:** Severe comorbidities can lead to "dose reductions," where the strength of the medication is lowered to prevent organ failure or systemic dysfunction
- **Completion Rates:** Patients with multiple comorbidities are statistically less likely to complete a full course of radiation or chemotherapy due to increased side effects and physical strain

Cost-Smart Options

Clinical Alternatives: Biosimilars and Generics

For many high-cost biologic drugs, "generic-like" versions called biosimilars are now available. These are FDA-approved as safe and effective as the original brand-name drugs but are often significantly less expensive.

- **HER2-Targeted Biosimilars:** Multiple biosimilars exist for Herceptin (trastuzumab), including *Hercessi*, *Kanjinti*, *Herzuma*, and *Ogivri*
- **Supportive Care Biosimilars:** Biosimilars for white blood cell boosters (like *Neulasta* or *Neupogen*) and bone-density medications (like *Xgeva*) are used to reduce the costs of managing treatment side effects
- **Generic Hormonal Therapies:** Many hormone-blocking pills (like *Tamoxifen* or *Anastrozole*) have been available as low-cost generics for years, often costing under $30 per month

Quality Metrics Tie-In

HEDIS/STAR Domain	Specific Breast Cancer Metric Tie-In	Documentation Requirement
Safety (PCR)	Plan All-Cause Readmission: Breast cancer patients have high 30-day readmission risk due to neutropenic fever or post-surgical infection	Document a post-discharge visit within 7 days focusing on fever monitoring, wound site assessment, and hydration status
Chronic Care (OMW)	Osteoporosis Management: 1 in 3 patients on Aromatase Inhibitors (AIs) develop significant bone loss or fractures	Document a DXA Scan (baseline and biennial) and initiation of bone-modifying therapy (e.g., bisphosphonates) if T-score is <-2.0
Effectiveness (FMC)	Follow-Up After ER Visit: High rates of ED visits for chemo-induced nausea or uncontrolled pain in MBC patients	Document a follow-up visit (telehealth or in-person) within 7–14 days to update the supportive care plan and anti-emetic regimen
Prevention (BCS-E)	Breast Cancer Screening: Ensuring women 40–74 have regular mammograms (New 2026 age alignment)	Document the date and type of mammogram (Screening vs. Diagnostic). If skipped, document a specific clinical exclusion (e.g., bilateral mastectomy or palliative status)
Patient Experience (CAHPS)	Care Coordination: Measuring how well the oncology team coordinates with Cardiology (for HER2+ cardiotoxicity) and Primary Care	Use the CAHPS Cancer Care Survey to track patient ratings on "Exchanging Information" and "Care Team Communication" regarding side effect management

HEDIS/STAR Domain	Specific Breast Cancer Metric Tie-In	Documentation Requirement

Abbreviations: AI, Aromatase Inhibitor; BCS-E, Breast Cancer Screening (Electronic Clinical Data Systems); BI-RADS, Breast Imaging-Reporting and Data System; CAHPS, Consumer Assessment of Healthcare Providers and Systems; DXA, Dual-Energy X-ray Absorptiometry; ED, Emergency Department; ECDS, Electronic Clinical Data System; FMC, Follow-Up After Emergency Department Visit for People with Multiple High-Risk Chronic Conditions; HEDIS, Healthcare Effectiveness Data and Information Set; MBC, Metastatic Breast Cancer; OMW, Osteoporosis Management in Women Who Had a Fracture; PCR, Plan All-Cause Readmissions; STAR, CMS Star Ratings

5. CODING REMINDERS & CASE EXAMPLES BOX

Specificity Requirements

Critical Element	Clinical Requirement	Example Documentation
Stage & Receptor Status	Specify the anatomical stage (TNM) and the status of ER, PR, and HER2	Stage IV (T2N1M1) Invasive Ductal Carcinoma. Receptor status: ER+ (90%), PR+ (70%), HER2-low (IHC 1+)
Genetic Etiology	Link the malignancy to specific germline or somatic mutations (e.g., BRCA1/2, PIK3CA, ESR1)	Metastatic HER2-negative disease with Germline BRCA1 mutation; currently on PARP inhibitor therapy
Validation Data	Include objective findings from imaging (RECIST criteria) or tumor markers (CA 15-3/CEA)	CT Abdomen (01/05/26): 2.4cm hepatic lesion (Segment IV); stable per RECIST 1.1. CA 15-3: 45 U/mL (improved from 60)
Complications & Toxicity	Explicitly link secondary conditions to the primary cancer or the specific treatment	Medication-induced Osteoporosis (M81.8) secondary to long-term Aromatase Inhibitor (AI) therapy; T-score -2.1 at distal femur

Abbreviations: AI, Aromatase Inhibitor; BRCA1/2, Breast Cancer Gene 1/2; CA 15-3, Cancer Antigen 15-3 (Tumor Marker); CEA, Carcinoembryonic Antigen (Tumor Marker); CT, Computed Tomography; ER, Estrogen Receptor; ESR1, Estrogen Receptor 1 Gene; HER2, Human Epidermal Growth Factor Receptor 2; IHC, Immunohistochemistry; M, Metastasis; N, Node; PARPi, Poly (ADP-ribose) Polymerase inhibitor; PIK3CA, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha; PR, Progesterone Receptor; RECIST, Response Evaluation Criteria in Solid Tumors; T, Tumor; TNM, Tumor, Node, Metastasis

Annual Clinical Review and Confirmation

Requirement	Breast Cancer (Malignant Neoplasm of Breast) Standards
Documentation Frequency	The active malignancy or ongoing treatment status must be documented annually with MEAT (Monitor, Evaluate, Assess, Treat) by 12/31
Face-to-Face	Required (In-person or synchronized audio-visual telehealth visits are eligible)
Precision	Must specify Site (e.g., Upper-outer quadrant), Laterality (Left/Right), Gender, and Current vs. History of status

Abbreviations: F2F, Face-to-Face; HCC, Hierarchical Condition Category; MEAT, Monitor, Evaluate, Assess, Treat; RAF, Risk Adjustment Factor; V28, Version 28 CMS-HCC Model

Good Documentation is Comprehensive Coding

Requirement	Breast Cancer (Malignant Neoplasm) Standards
Documentation Frequency	YES—Active malignancy, metastatic sites, or ongoing hormonal/targeted therapy must be documented annually with MEAT by 12/31
Face-to-Face	Required (In-person or synchronized audio-visual telehealth counts)
Precision	Must specify Laterality (Right/Left), Anatomic Site (e.g., Upper-outer quadrant), and Receptor Status (ER/PR/HER2)

Abbreviations: ER/PR/HER2, Estrogen Receptor/Progesterone Receptor/Human Epidermal Growth Factor Receptor 2; F2F, Face-to-Face; HCC, Hierarchical Condition Category; MEAT, Monitor, Evaluate, Assess, Treat; RAF, Risk Adjustment Factor; V28, Version 28 CMS-HCC Model

EHR Tips

Feature	EHR Configuration Tip	Clinical & Quality Impact
Auto-Classification	Receptor & Mutation Mapper: Auto-populates problem lists with specific tumor phenotypes (e.g., ER+, HER2-low, BRCA1 mut) from pathology interfaces	Bridging the gap between pathology results and the clinician's active workspace (the Problem List); Ensures patient is flagged for specific therapeutic interventions
Alert Systems	Surveillance Alert: Flags if no imaging (Mammogram/CT) or tumor markers have been documented in the last 4–6 months	Supports BCS-E (Breast Cancer Screening) guidelines and prevents delays in detecting progression
BPA (Best Practice Advisory)	Bone Health Flag: Triggers for patients on Aromatase Inhibitors (AIs) to ensure an annual DXA scan and bone-modifying therapy are addressed	Closes the OMW (Osteoporosis Management) HEDIS gap and reduces fracture risk
Problem List Prompts	"Metastatic Site" Hard-Stop: Mandatory field for "Secondary Site" (e.g., Bone, Liver, Lung) when adding a Stage IV diagnosis	Stratify disease severity and provide insight for treatment
Outcome Tracking	ePRO Integration: Automated patient portal prompts for the FACT-B or CAHPS Cancer Care survey prior to visits	Provides objective longitudinal data

Abbreviations: AI, Aromatase Inhibitor; BCS-E, Breast Cancer Screening (Electronic Clinical Data System); BPA, Best Practice Advisory; CAHPS, Consumer Assessment of Healthcare Providers and Systems; DXA, Dual-Energy X-ray Absorptiometry; EHR, Electronic Health Record; ePRO, Electronic Patient-Reported Outcomes; ER, Estrogen Receptor; FACT-B, Functional Assessment of Cancer Therapy - Breast; HCC, Hierarchical Condition Category; HER2, Human Epidermal Growth Factor Receptor 2; MEAT, Monitor, Evaluate, Assess, Treat; MIPS, Merit-based Incentive Payment System; OMW, Osteoporosis Management in Women Who Had a Fracture; PR, Progesterone Receptor; RAF, Risk Adjustment Factor; V28, Version 28 CMS-HCC Risk Adjustment Model

Brief Case Examples

SUCCESS CASE: "62yo female with active metastatic breast cancer to the lumbar spine (C79.51) and liver (C78.7). Disease is ER+/PR+, HER2-low. CT Abdomen (11/15/2025): Stable 2cm hepatic lesion. Currently tolerating CDK 4/6 inhibitor and Letrozole; continuing current regimen"

- **Result:** Appropriately documents metastatic cancer stage, receptor status, and treatment regime (HCC 18, RAF: ~2.341)

PITFALL CASE: "Patient has Stage IV breast cancer. Doing well on medications. No new complaints. Follow up in 3 months."

- **Result:** Documentation fails to specify the secondary site of metastasis (required for HCC 18) and lacks MEAT evidence (no specific medication named, no exam findings or lab review cited). Loss of metastatic RAF weight (~2.341). Risk of potential $24,351.88/year clawback and impact on standards of care

FIX: "Active invasive ductal carcinoma of the right upper-outer quadrant (C50.411), ER+/HER2-. Currently on adjuvant Anastrozole (AI). Monitoring for AI-induced osteoporosis (M81.8); DXA Scan (12/01/2025) shows T-score of -2.2. Patient encouraged to continue weight-bearing exercise"

- **Result:** Appropriately documents Malignant Neoplasms of the Breast (HCC 23)Ap. * RAF maintained: ~0.186 (Varies based on age/disability status)

Appendix

Detailed Screening Recommendations

American Cancer Society (ACS) recommends the following:[43]

- Women between 40 and 44 have the option to start screening with a mammogram every year
- Women 45 to 54 should get mammograms every year
- Women 55 and older can switch to a mammogram every other year, or they can choose to continue yearly mammograms. Screening should continue as long as a woman is in good health and is expected to live at least 10 more years

American Cancer Society (ACS): Women who are at high risk for breast cancer based on certain factors should get a breast MRI and a mammogram every year, typically starting at age 30. This includes women who:

- Have a lifetime risk of breast cancer of about 20% to 25% or greater, according to risk assessment tools that are based mainly on family history (see below)
- Have a known *BRCA1* or *BRCA2* gene mutation (based on having had genetic testing)
- Have a first-degree relative (parent, brother, sister, or child) with a *BRCA1* or *BRCA2* gene mutation, and have not had genetic testing themselves
- Had radiation therapy to the chest before they were 30 years old
- Have Li-Fraumeni syndrome, Cowden syndrome, or Bannayan-Riley-Ruvalcaba syndrome, or have first-degree relatives with one of these syndromes

ACS recommends against MRI screening for women whose lifetime risk of breast cancer is less than 15%.

United States Preventative Task Force (USPTF) recommends the following:[47]

- Women aged 40 to 74: biennial screening mammography
- Women 75 or older: USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women 75 or older
- Women with dense breasts: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of supplemental screening for breast cancer using breast ultrasonography or MRI in women identified to have dense breasts on an otherwise negative screening mammogram

American College of Radiology (ACR): Strongly advocates for annual screening starting at age 40 for women of average risk.[4]

The American College of Obstetricians and Gynecologists Screening Recommendations ACOG (OB-GYNs) recommends the following:[48]

- **Patients aged 19 and older:**
  - Clinical breast exams (CBEs) every 1-3 years for ages 25-39 and annually for ages 40+

    - Breast self-awareness is encouraged to help detect palpable breast cancer; however, routine breast self-examinations are not recommended
- **Patients aged 40 to 75:**
    - Screening mammography should be performed every 1 to 2 years. Women at average risk for breast cancer should undergo screening mammography every 1 or 2 years. This decision should be based on an informed, shared decision-making process that includes discussions about the benefits and harms of annual versus biennial screening, as well as the incorporation of patient values and preferences
    - Biennial screening mammography, especially for women aged 55 and older, is a reasonable option to minimize potential harm. However, patient counseling should emphasize that reducing the frequency of screening may also lead to a decrease in the benefits of early detection
    - Women at average risk of breast cancer should continue screening mammography until at least age 75. Decisions regarding the continuation or discontinuation of screening should not be based solely on age
- **Patients aged 75 or older:**
    - The decision to discontinue screening mammography should be guided by a shared decision-making process that takes into account the woman's health status and life expectancy
    - While breast self-awareness can help detect palpable breast cancer and is encouraged, routine breast self-examinations are not recommended

American College of Radiology (ACR): Strongly advocates for annual screening starting at age 40 for women of average risk.

Staging & Diagnosis

1. The Three Staging Timelines

- Clinical (cTNM): Determined preoperatively via physical exam and imaging (Mammography, US, or MRI)
- Pathologic (pTNM): Determined after surgery by examining the actual tumor and lymph nodes
- Neoadjuvant (ypTNM): The "y" prefix signifies staging performed after a patient has received neoadjuvant treatment (chemotherapy/radiation before surgery) to assess the treatment's effect on the tumor burden

2. Pathologic Component Breakdown

Primary Tumor (T)

- Assessed via imaging (Mammography, US, MRI) and clinical exam
- MRI is particularly vital when mammography fails to clearly identify a mass or accurately measure its dimensions

The "T" category describes the size and local extent of the primary tumor:

Category	Definition
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma in situ (non-invasive)
T1	Tumor ≤20 mm in greatest dimension
T1mi	Tumor ≤1 mm in greatest dimension
T1a	Tumor >1 mm but ≤5 mm
T1b	Tumor >5 mm but ≤10 mm
T1c	Tumor >10 mm but ≤20 mm
T2	Tumor >20 mm but ≤50 mm
T3	Tumor >50 mm
T4	Tumor of any size with direct extension to the chest wall and/or skin (ulceration/nodules)
T4d	Inflammatory carcinoma

Lymph Nodes (N)

- Clinical palpation is unreliable: It has a low Negative Predictive Value (50–60%), meaning many non-palpable nodes actually contain cancer
- Formal axillary staging (e.g., Sentinel Lymph Node Biopsy) is required because nodal status is the most critical prognostic factor in early-stage disease

Category	Definition
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastases
N1	Metastases to movable ipsilateral level I, II axillary lymph node(s)
N2	Metastases in ipsilateral level I, II axillary nodes that are fixed/matted (N2a) or clinically detected internal mammary nodes in the absence of axillary involvement (N2b)
N3	Metastases in infraclavicular (level III axillary) nodes (N3a), both internal mammary and axillary nodes (N3b), or supraclavicular nodes (N3c)

Metastasis (M)

- Routine staging is NOT recommended for Stage I or II patients with ≤3 nodes and no symptoms
- Systemic work-up (CT/PET/Bone Scans) is restricted to:
  - Locally advanced disease (T3+, N2, or N3)
  - Inflammatory breast cancer
  - Symptomatic patients (e.g., bone pain, jaundice)

Category	Definition
M0	No clinical or radiographic evidence of distant metastases
cM0(i+)	No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically detected tumor cells in circulating blood, bone marrow, or other nonregional nodal tissue that are no larger than 0.2 mm in a patient without symptoms or signs of metastases
M1	Distant detectable metastases as determined by classic clinical and radiographic means and/or histologically proven larger than 0.2 mm

Anatomic Staging

- **Stage 0 (Tis):** Carcinoma in situ (non-invasive)
- **Stage I (IA, IB):** Small tumors with minimal or no nodal involvement
- **Stage II (IIA, IIB):** Larger tumors or involvement of 1–3 regional lymph nodes
  - **Stage III (IIIA, IIIB, IIIC):** Locally advanced disease; involvement of skin/chest wall or extensive nodal involvement (N2/N3)
  - **Stage IV (M1):** Distant metastatic disease

Full Staging Chart

Primary Tumor (T)	Regional Lymph Nodes (N)	Distant Metastasis (M)	Anatomic Stage
Tis	N0	M0	0
T1	N0	M0	IA
T0	N1mi	M0	IB
T1	N1mi	M0	IB
T0	N1	M0	IIA
T1	N1	M0	IIA
T2	N0	M0	IIA
T2	N1	M0	IIB
T3	N0	M0	IIB
T0	N2	M0	IIIA
T1	N2	M0	IIIA
T2	N2	M0	IIIA
T3	N1	M0	IIIA
T3	N2	M0	IIIA
T4	N0	M0	IIIB

Primary Tumor (T)	Regional Lymph Nodes (N)	Distant Metastasis (M)	Anatomic Stage
T4	N1	M0	IIIB
T4	N2	M0	IIIB
Any T	N3	M0	IIIC
Any T	Any N	M1	IV

Prognostic Staging

Breast carcinoma TNM clinical prognostic stage groups AJCC UICC 8th edition

If TNM is...	And Grade is...	HER2 Status	ER Status	PR Status	Prognostic Stage
Tis, N0, M0	Any	Any	Any	Any	0
T1, N0, M0	G1	Negative	Positive	Positive/Negative	IA
T1, N0, M0	G2	Negative	Positive	Positive/Negative	IA
T1, N0, M0	G3	Negative	Positive	Positive/Negative	IB
T2, N0, M0	G1	Negative	Positive	Positive	IA
T2, N1, M0	G1	Positive	Positive	Positive	IB
T2, N1, M0	G2	Positive	Negative	Negative	IIIA
T3, N1, M0	G3	Negative	Negative	Negative	IIIC
Any T, N, M1	Any	Any	Any	Any	IV

Breast carcinoma TNM **pathologic prognostic stage** groups AJCC UICC 8th edition

If TNM is...	And Grade is...	HER2 Status	ER Status	PR Status	Prognostic Stage
T1, N0, M0	G1, G2, or G3	Positive	Positive	Positive/Negative	IA
T1, N0, M0	G1	Negative	Positive	Positive/Negative	IA
T1, N0, M0	G2 or G3	Negative	Positive	Positive/Negative	IB
T2, N1, M0	G1	Positive	Positive	Positive	IB
T2, N1, M0	G2	Positive	Negative	Negative	IIIA
T2, N1, M0	G3	Negative	Negative	Negative	IIIB
T4, N2, M0	Any G	Negative	Negative	Negative	IIIC
Any T, N, M1	Any G	Any Status	Any Status	Any Status	IV

Full Breast Cancer Staging Pathway

[START: Clinical Presentation]

- **Action:** Physical Exam + Mammogram/Ultrasound
- **Result:** Initial **Clinical T** (size) and **Clinical N** (palpable nodes) estimates
  - **Is there evidence of distant spread?** (CT, Bone Scan, PET)
    - **YES → STAGE IV (Metastatic)** → *Systemic Therapy*
    - **NO → Proceed to Biopsy**

[STEP 2: Tissue Biopsy & Biomarker Analysis]

- **Action:** Core Needle Biopsy of mass (and nodes if suspicious).
- **Lab Analysis (The "Biological Blueprint"):**
  - **Histologic Grade:** G1 (Well-diff) to G3 (Poorly-diff)
  - **ER/PR Status:** Positive if >1%
  - **HER2 Status:** Positive if IHC 3+ or FISH ratio ≥2.0

[STEP 3: Clinical Prognostic Stage]

- **Integration:** Combine **cTNM** + **Grade** + **Biomarkers**.
- **Treatment Decision:**
  - **Neoadjuvant Therapy:** (Chemo/Endocrine therapy first to shrink tumor)
  - **Primary Surgery:** (Proceed directly to Step 4)

[STEP 4: Surgical Resection]

- **Action:** Lumpectomy or Mastectomy + Single lymph node biopsy or Axillary Dissection
- **Result:** Definitive **Pathologic T** (size in mm) and **Pathologic N** (node count)

[STEP 5: Genomic Assays] *(If Applicable)*

- **Criteria:** Usually ER+, HER2-, Lymph Node Negative
- **Action:** Oncotype DX, MammaPrint, etc
- **Impact:** If **Low Recurrence Score** → Potential **Downstaging** to **Stage IA** (spares chemotherapy)

[STEP 6: FINAL Pathological Prognostic Stage]

- **Integration of all data: pTNM** + **Biomarkers** + **Grade** + **Genomics**
- **Final Output:** Used for definitive prognosis and adjuvant (post-surgery) treatment planning

Treatment Options for Breast Cancer - Dependent on Type[27,49]

Hormone Receptor-Positive (HR+), HER2-Negative Disease

For this group, the primary goal is to use effective treatments that have fewer side effects than traditional chemotherapy.

- **Preferred Initial Treatment:** Most patients should start with **Endocrine Therapy (ET)** combined with a **CDK 4/6 inhibitor**. This combination is generally as effective as chemotherapy but is much less toxic
- **When to Use Chemotherapy:**
  - **Visceral Crisis:** For the small number of patients with extensive organ involvement (visceral metastases) where a rapid response is needed, though data does not show a definitive survival advantage over ET
  - **Endocrine Resistance:** If the cancer progresses despite multiple lines of ET or shows rapid resistance to hormone-based treatments
- **Special Cases:** Patients with *BRCA1/2* mutations may have additional targeted options (like PARP inhibitors) considered within this framework

Hormone Receptor-Negative, HER2-Negative (Triple-Negative) Disease

Triple-negative breast cancer (TNBC) is typically more aggressive than other subtypes. Because the cancer lacks the three primary receptors (ER, PR, and HER2), it does not respond to hormone therapy or HER2-targeted drugs.

- **Primary Treatment:** The standard of care is **chemotherapy**, often used in combination with **immunotherapy** (depending on PD-L1 status)

Subtype	Recommended First-Line	Rationale
HR+/HER2-	Endocrine Therapy + CDK 4/6 Inhibitor	Lower toxicity; comparable survival outcomes to chemotherapy
Triple-Negative	Chemotherapy +/- Immunotherapy	Aggressive disease phenotype; lacks targets for hormone therapy

Abbreviations: AI, Aromatase Inhibitor; BC, Breast Cancer; CDK 4/6, Cyclin-Dependent Kinase 4 and 6; ER, Estrogen Receptor; HER2-, Human Epidermal Growth Factor Receptor 2 (Negative); HR+, Hormone Receptor Positive; I-O, Immuno-Oncology; OS, Overall Survival; PFS, Progression-Free Survival; PR, Progesterone Receptor; TNBC, Triple-Negative Breast Cancer

The treatment landscape for Triple-Negative Breast Cancer (TNBC) and HER2-negative cancers with specific genetic mutations is centered on identifying biomarkers that allow for targeted therapy over standard chemotherapy.

Triple-Negative Breast Cancer (TNBC)

- **First-Line Treatment:** Guided primarily by **PD-L1 expression**
  - **PD-L1 Positive:** Treatment typically involves an immune checkpoint inhibitor plus chemotherapy
  - **PD-L1 Negative:** Standard chemotherapy is used (either a single agent or a combination)
- **Later-Line Treatment: Sacituzumab govitecan (Trodelvy)**, an antibody-drug conjugate (ADC), is FDA-approved for patients who have already received at least two prior systemic therapies
- **Emerging Therapies:** New ADCs like *datopotamab deruxtecan* are showing promise but are not yet standard first-line options

PARP Inhibitors (Olaparib and Talazoparib)

PARP inhibitors are more effective and less toxic than traditional chemotherapy for a specific subset of patients.

- **Eligibility:** Patients with **HER2-negative** MBC who have:
  - **Germline BRCA1/2** mutations (inherited)
  - **Somatic BRCA1/2** mutations (found only in the tumor)
  - **Germline PALB2** mutations
- **Clinical Benefits:** * **Better Results:** Trials (*OlympiAD* and *EMBRACA*) showed significantly improved progression-free survival (PFS) compared to chemotherapy
  - **Better Quality of Life:** Patients reported improved well-being and fewer severe side effects (though anemia is a common side effect of these drugs)
- **Administration:** These are oral medications used sequentially (before or after chemotherapy), not at the same time as chemotherapy or CDK 4/6 inhibitors

HER2-Low and HER2-Ultralow[34]

A new category of "HER2-negative" cancer has emerged for patients whose tumors have very low levels of the HER2 protein.

- **Treatment: Trastuzumab deruxtecan (T-DXd)** is approved for patients with:
  - Hormone receptor-positive disease that no longer responds to endocrine therapy
  - HER2 scores of **IHC 1+ or 2+** (with a negative ISH test), or even **IHC 0 with membrane staining** (ultralow)
- **Requirement:** Status must be confirmed by an FDA-approved test

Marker/Mutation	Targeted Therapy	Setting
PD-L1 Positive	Immunotherapy + Chemo	First-line TNBC
BRCA1/2 or PALB2	PARP Inhibitors	HER2-negative (after prior chemo)
HER2-Low/Ultralow	T-DXd (Enhertu)	Endocrine-refractory HR+ or TNBC
TROP-2	Sacituzumab govitecan	Later-line TNBC

Abbreviations: ADC, Antibody-Drug Conjugate; BRCA1/2, Breast Cancer Gene 1/2; CPS, Combined Positive Score (PD-L1 measurement); HR+, Hormone Receptor Positive; I-O, Immuno-Oncology; PALB2, Partner and Localizer of BRCA2; PARPi, Poly (ADP-ribose) Polymerase inhibitor; PD-L1, Programmed Death-Ligand 1; T-DXd, Trastuzumab Deruxtecan; TNBC, Triple-Negative Breast Cancer; TROP-2, Trophoblast Cell-Surface Antigen 2

Hormone Receptor-Positive (HR+), HER2-Positive Disease[34]

For patients with **HER2-positive** metastatic breast cancer, the foundation of treatment is **HER2-directed therapy**, which has been proven to improve survival rates. The specific treatment plan depends on whether the cancer also expresses hormone receptors.

Patients in this category have three main "tools" available for treatment: chemotherapy, endocrine therapy, and HER2-directed therapy.

- **The Standard:** HER2-directed therapy should always be part of the first-line treatment
- **The Debate:** It is not yet clear whether it is better to pair the HER2-directed therapy with **chemotherapy** or **endocrine therapy** as the very first step. The choice often depends on the urgency of the clinical situation and patient factors

Hormone Receptor-Negative (HR-), HER2-Positive Disease[34]

Because these tumors do not rely on hormones to grow, endocrine therapy is not an option.

- **The Standard:** The recommended first-line treatment for patients who have not yet received therapy (treatment-naïve) is a combination of **HER2-directed therapy plus chemotherapy**

Subtype	Recommended Components	Key Consideration
HR+/HER2+	HER2-directed therapy + (Chemo OR Endocrine Therapy)	HER2-directed therapy is essential; the partner drug varies
HR-/HER2+	HER2-directed therapy + Chemotherapy	This is the standard for patients who have not been treated yet

REFERENCES

1. Menon G, Alkabban FM, Ferguson T. Breast Cancer. In: *StatPearls*. StatPearls Publishing; 2025. Accessed January 8, 2026. http://www.ncbi.nlm.nih.gov/books/NBK482286/
2. 2026 ICD-10-CM Codes C50∗: Malignant neoplasm of breast. Accessed January 8, 2026. https://www.icd10data.com/ICD10CM/Codes/C00-D49/C50-C50/C50-
3. Cancer of the Breast (Female) - Cancer Stat Facts. SEER. Accessed January 8, 2026. https://seer.cancer.gov/statfacts/html/breast.html
4. Monticciolo DL, Malak SF, Friedewald SM, et al. Breast cancer screening recommendations inclusive of all women at average risk: update from the ACR and Society of Breast Imaging. *J Am Coll Radiol*. 2021;18(9):1280-1288.
5. 2025-cancer-facts-and-figures-acs.pdf.
6. Amin MB, Edge SB, Greene FL, et al. *AJCC Cancer Staging Manual*. Vol 1024. Springer; 2017.
7. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *Arch Pathol Lab Med*. 2018;142(11):1364-1382.
8. Hortobagyi GN, Edge SB, Giuliano A. New and important changes in the TNM staging system for breast cancer. *Am Soc Clin Oncol Educ Book*. 2018;38:457-467.
9. Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer. *Ann Surg Oncol*. 2018;25(7):1783-1785. doi:10.1245/s10434-018-6486-6
10. Breast Cancer Gene, Protein, and Blood Tests. Accessed March 5, 2026. https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/other-breast-cancer-gene-protein-blood-tests.html
11. Runowicz CD, Leach CR, Henry NL, et al. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. *J Clin Oncol*. 2016;34(6):611-635.
12. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin*. 2007;57(2):75-89.

13. Survival Rates for Breast Cancer. Accessed January 9, 2026. https://www.cancer.org/cancer/types/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html
14. Survival Rates and Prognosis for Breast Cancer - NCI. December 2, 2025. Accessed January 9, 2026. https://www.cancer.gov/types/breast/survival
15. Sun L, Legood R, dos-Santos-Silva I, Gaiha SM, Sadique Z. Global treatment costs of breast cancer by stage: A systematic review. *PLoS ONE*. 2018;13(11):e0207993. doi:10.1371/journal.pone.0207993
16. Wilkinson AN, Seely JM, Rushton M, et al. Capturing the True Cost of Breast Cancer Treatment: Molecular Subtype and Stage-Specific per-Case Activity-Based Costing. *Curr Oncol*. 2023;30(9):7860-7873. doi:10.3390/curroncol30090571
17. Salemis NS, Mourtzoukou E, Angelopoulos M. Subtle signs of breast cancer as an important pitfall in mammographic interpretation: Establishing an accurate diagnosis in an equivocal case. *Breast Dis*. 2021;40(3):213-218.
18. Breast Cancer Risk Factors You Can't Change. Accessed January 11, 2026. https://www.cancer.org/cancer/types/breast-cancer/risk-and-prevention/breast-cancer-risk-factors-you-cannot-change.html
19. Inflammatory Breast Cancer | Details, Diagnosis, and Signs. Accessed January 11, 2026. https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer/inflammatory-breast-cancer.html
20. CDC. Symptoms of Breast Cancer. Breast Cancer. July 30, 2025. Accessed January 11, 2026. https://www.cdc.gov/breast-cancer/symptoms/index.html
21. Lamb LR, Mohallem Fonseca M, Verma R, Seely JM. Missed breast cancer: effects of subconscious bias and lesion characteristics. *Radiographics*. 2020;40(4):941-960.
22. Vadakekut ES, Puckett Y. New Palpable Breast Mass. In: *StatPearls*. StatPearls Publishing; 2025. Accessed March 5, 2026. http://www.ncbi.nlm.nih.gov/books/NBK560757/
23. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med*. 2013;368(11):987-998.
24. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. *Cancer Interdiscip Int J Am Cancer Soc*. 2003;97(11):2869-2879.
25. Barish R, Lynce F, Unger K, Barac A. Management of cardiovascular disease in women with breast cancer. *Circulation*. 2019;139(8):1110-1120.
26. Rosen RD, Sapra A. TNM Classification. In: *StatPearls*. StatPearls Publishing; 2025. Accessed January 12, 2026. http://www.ncbi.nlm.nih.gov/books/NBK553187/
27. Breast Cancer Treatment | Treatment Options for Breast Cancer. Accessed January 12, 2026. https://www.cancer.org/cancer/types/breast-cancer/treatment.html
28. cancer CCS/ S canadienne du. Treatments for metastatic breast cancer. Canadian Cancer Society. March 2024. Accessed March 5, 2026. https://cancer.ca/en/cancer-information/cancer-types/breast/treatment/metastatic
29. Breast Cancer Clinical Guidelines | Breast Cancer Surgery Melbourne, VIC. Accessed March 5, 2026. https://www.melbournebreastcancersurgery.com.au/breast-cancer-clinical-guidelines.html
30. Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial. *Lancet Oncol*. 2011;12(11):1032-1044. doi:10.1016/S1470-2045(11)70199-1
31. Gilbert FJ, Pinker-Domenig K. Diagnosis and Staging of Breast Cancer: When and How to Use Mammography, Tomosynthesis, Ultrasound, Contrast-Enhanced Mammography, and Magnetic Resonance Imaging. In: Hodler J, Kubik-Huch RA, von Schulthess GK, eds. *Diseases of the Chest, Breast, Heart and Vessels 2019-2022: Diagnostic and Interventional Imaging*. IDKD Springer Series. Springer; 2019. Accessed January 12, 2026. http://www.ncbi.nlm.nih.gov/books/NBK553859/
32. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. *J Clin Oncol*. 2013;31(19):2382-2387. doi:10.1200/JCO.2012.45.2615

33. Lewis P, Brunt A, Coles C, Griffin S, Locke I, Roques T. Moving forward fast with FAST-Forward. *Clin Oncol*. 2021;33(7):427-429.
34. Vaidya JS, Bulsara M, Baum M, et al. Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. *Bmj*. 2020;370.
35. Julian T, Costantino J, Vicini F, et al. Early toxicity results with 3-D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation (APBI) trial. *Int J Radiat Oncol Biol Phys*. 2011;81(2):S7.
36. Patient Guide to Tumor Markers | OncoLink. Accessed January 12, 2026. https://www.oncolink.org/cancer-treatment/procedures-diagnostic-tests/blood-tests-tumor-diagnostic-tests/patient-guide-to-tumor-markers#:~:text=Tumor%20markers%20are%20often%20used,it%20has%20grown%20and%20spread.
37. Lawrence R, Watters M, Davies CR, Pantel K, Lu YJ. Circulating tumour cells for early detection of clinically relevant cancer. *Nat Rev Clin Oncol*. Published online June 2, 2023:1-14. doi:10.1038/s41571-023-00781-y
38. Griffeth LK. Use of PET/CT scanning in cancer patients: technical and practical considerations. *Proc Bayl Univ Med Cent*. 2005;18(4):321-330. doi:10.1080/08998280.2005.11928089
39. Stage 2 Breast Cancer Overview. National Breast Cancer Foundation. Accessed January 12, 2026. https://www.nationalbreastcancer.org/breast-cancer-stage-2/
40. Agarwal R, Epstein AS. The Role of Palliative Care in Oncology. *Semin Interv Radiol*. 2017;34(4):307-312. doi:10.1055/s-0037-1608702
41. Guo Y, Truong AN. Rehabilitation Of Patients With Breast Cancer. In: Hunt KK, Robb GL, Strom EA, Ueno NT, eds. *Breast Cancer 2nd Edition*. Springer; 2008:485-504. doi:10.1007/978-0-387-34952-7_17
42. Sullivan DC, Schwartz LH, Zhao B. The Imaging Viewpoint: How Imaging Affects Determination of Progression-free Survival. *Clin Cancer Res Off J Am Assoc Cancer Res*. 2013;19(10):2621-2628. doi:10.1158/1078-0432.CCR-12-2936
43. ACS Breast Cancer Screening Guidelines. Accessed January 8, 2026. https://www.cancer.org/cancer/types/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html
44. Guidelines Detail. NCCN. Accessed January 13, 2026. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1457
45. Mukherjee A, Gu Z, Chen LH, Chlebowski RT, Potosky AL, Haque R. Comorbidity burden and risk of second primary non-breast cancer in breast cancer survivors. *Cancer Epidemiol*. 2025;97:102867. doi:10.1016/j.canep.2025.102867
46. Walsh RL, Lofters AK, Moineddin R, Krzyzanowska MK, Grunfeld E. The effect of comorbidity on primary care use during breast cancer chemotherapy: a population-based retrospective cohort study using CanIMPACT data. *CMAJ Open*. 2021;9(2):E331-E341. doi:10.9778/cmajo.20200166
47. US Preventive Services Task Force, Nicholson WK, Silverstein M, et al. Screening for Breast Cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2024;331(22):1918. doi:10.1001/jama.2024.5534
48. ACOG Updates Recommendation on When to Begin Breast Cancer Screening Mammography. Accessed January 8, 2026. https://www.acog.org/news/news-releases/2024/10/acog-updates-recommendation-when-to-begin-breast-cancer-screening-mammography
49. PDQ Adult Treatment Editorial Board. Breast Cancer Treatment (PDQ®): Patient Version. In: *PDQ Cancer Information Summaries*. National Cancer Institute (US); 2002. Accessed March 9, 2026. http://www.ncbi.nlm.nih.gov/books/NBK65969/

Medical Disclaimer

The information provided by the American Academy of Value-Based Care (AAVBC) in this document, including but not limited to coding guidance, and related content, is intended for educational and informational purposes only. This content is designed to assist healthcare providers, organizations, and professionals in understanding and applying Value-Based Care principles, practices, and regulatory compliance standards.

AAVBC does not provide legal, clinical, or medical advice. The content presented should not be interpreted or relied upon as specific legal, medical, clinical, or professional guidance. While efforts are made to ensure the accuracy and currency of the information provided, AAVBC does not guarantee that the materials presented are complete, comprehensive, or without error.

Providers and healthcare professionals must independently evaluate all content and guidance presented herein in the context of applicable laws, regulations, clinical guidelines, payer policies, patient-specific conditions, and contraindications. Any treatments, procedures, diagnostic approaches, medications, or strategies discussed are illustrative and should not be directly applied without a thorough and independent review of current, evidence-based clinical resources, and regulatory requirements.

For coding, documentation, utilization management, quality measures (including STAR ratings), and compliance matters, users are responsible for consulting official guidelines issued by regulatory bodies, including but not limited to the Centers for Medicare & Medicaid Services (CMS), the American Medical Association (AMA), relevant state agencies, and other authoritative entities.

AAVBC expressly disclaims liability for any loss, claim, or damages arising directly or indirectly from the use or reliance on information provided in this document. Users should consult their organization's legal counsel, compliance officer, or qualified professional advisor for advice specific to their situation.

By accessing and using this document, you agree to AAVBC's terms and acknowledge that the use of the content is at your own risk and discretion.